1 **Title:**

High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T
 cells that include proliferative memory cells.

4

5 One Sentence Summary

Individuals with low neutralising antibody titres may be at risk of SARS-CoV-2 re-infection due to a
failure to generate a high quality CD4 T cell response specific for receptor binding domain (RBD),
including memory CD4 T cells that proliferate in vitro in response to RBD, and which are also
therefore an important target for vaccine design.

10

11 Authors:

12 Chansavath Phetsouphanh¹, Weng Hua Khoo^{2,3}, Katherine Jackson², Vera Klemm¹, Annett Howe¹,

13 Anupriya Aggarwal¹, Anouschka Akerman¹, Vanessa Milogiannakis¹, Alberto Ospina Stella¹, Romain

14 Rouet², Peter Schofield², Megan L. Faulks², Hannah Law¹, Thidarat Danwilai⁶, Mitchell Starr⁶, C. Mee

15 Ling Munier¹, Daniel Christ², Mandeep Singh^{2,3}, Peter I Croucher², Fabienne Brilot-Turville^{4,5}, Stuart

16 Turville¹, Tri Giang Phan^{2,3}, Gregory J Dore^{1,7}, David Darley⁷, Philip Cunningham⁶, Gail V Matthews¹,

- ⁷, Anthony D Kelleher^{1, 7*}, and John J Zaunders^{6*}
- 18

19 Affiliations:

- 20 ¹ Kirby Institute, UNSW, Sydney, Australia;
- ²Garvan Institute of Medical Research, Sydney, Australia;
- ³ St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia;
- ⁴ Brain and Mind Centre, Children's Hospital at Westmead, University of Sydney, Australia;
- ⁵ Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, Australia;
- ⁶ NSW State Reference Laboratory for HIV, St Vincent's Centre for Applied Medical Research,
- 26 Australia;
- 27 ⁷ St Vincent's Hospital Sydney, Australia
- 28 *These authors contributed equally

- 29 Correspondence: j.zaunders@amr.org.au
- 30
 Abstract
 230 words
 Text
 7602 (Methods: 3099)
- 31 Figures
- 32 Supplementary Figures 5
- 33 Supplementary Tables 2

RBD-specific memory CD4 T cells

34		
35	Chansavath Phetsouphanh	cphetsouphanh@kirby.unsw.edu.au
36	Weng Hua Khoo	w.khoo@garvan.org.au
37	Katherine Jackson	k.jackson@garvan.org.au
38	Vera Klemm	vklemm@kirby.unsw.edu.au
39	Annett Howe	annett.howe@hotmail.com
40	Anupriya Aggarwal	aaggarwal@kirby.unsw.edu.au
41	Anouschka Akerman	aakerman@kirby.unsw.edu.au
42	Vanessa Milogiannakis	vmilogiannakis@kirby.unsw.edu.au
43	Alberto Ospina Stella	a.ospina.stella@gmail.com
44	Romain Rouet	r.rouet@garvan.org.au
45	Peter Schofield	p.schofield@garvan.org.au
46	Megan L. Faulks	m.faulks@garvan.org.au
47	Hannah Law	hlaw@kirby.unsw.edu.au
48	Thidarat Danwilai	t.danwilai@amr.org.au
49	Mitchell Starr	m.starr@amr.org.au
50	C.Mee Ling Munier	cmunier@kirby.unsw.edu.au
51	Daniel Christ	d.christ@garvan.org.au
52	Mandeep Singh	m.singh@garvan.org.au
53	Peter I Croucher	p.croucher@garvan.org.au
54	Fabienne Brilot-Turville	fabienne.brilot@sydney.edu.au
55	Stuart Turville	sturville@kirby.unsw.edu.au
56	Tri Giang Phan	t.phan@garvan.org.au
57	Gregory J Dore	gdore@kirby.unsw.edu.au
58	David Darley	David.Darley@svha.org.au
59	Philip Cunningham	Philip.Cunningham@svha.org.au
60	Gail V Matthews	Gmatthews@kirby.unsw.edu.au
61	Anthony D Kelleher	akelleher@kirby.unsw.edu.au
62	John J Zaunders	j.zaunders@amr.org.au

RBD-specific memory CD4 T cells

63 ABSTRACT

64

65 Long-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated 66 immunity, is required in a very large majority of the population in order to reduce ongoing disease 67 burden. We have investigated the association between memory CD4 and CD8 T cells and levels of 68 neutralizing antibodies in convalescent COVID-19 subjects. Higher titres of convalescent neutralizing 69 antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously in vitro. Conversely, up to half of convalescent 70 71 individuals had low neutralizing antibody titres together with a lack of receptor binding domain (RBD)-72 specific memory CD4 T cells. These low antibody subjects had other, non-RBD, spike-specific CD4 T 73 cells, but with more of an inhibitory Foxp3+ and CTLA-4+ cell phenotype, rather than the effector T-74 bet+, cytotoxic granzymes+ and perforin+ cells seen in high antibody subjects. Single cell 75 transcriptomics of antigen-specific CD4+ T cells from high antibody subjects revealed heterogenous 76 RBD-specific CD4+ T cells that comprised central memory, transitional memory and Tregs, as well as 77 cytotoxic clusters containing diverse TCR repertoires, that were absent in individuals with low 78 antibody levels. However, vaccination in low antibody convalescent individuals led to a slight but 79 significant improvement in RBD-specific memory CD4 T cells and increased neutralizing antibody 80 titres. Our results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-81 region should be prioritized in booster vaccines.

82

RBD-specific memory CD4 T cells

84 INTRODUCTION

85

86 The question of the protective efficacy of both convalescent and vaccine induced immunity to SARS-87 CoV-2 is of global significance. This is highlighted by the multiple waves of infections, with rates of 88 population-wide protection against re-infection of only 50-80% protection during 2020, depending on 89 age (1), or an estimated 60% protection against symptomatic re-infection with the immuno-evasive 90 Omicron variant (2). In order to end the COVID-19 pandemic, a large proportion of the population will 91 need to be immune to the virus (3), or at least, if they become infected, to develop an immune response 92 which minimizes virus shedding, symptoms and onward transmission. Early studies concentrated on 93 serum antibody levels in recovered COVID-19 patients, and in particular neutralizing antibodies, since 94 it is believed that the most effective vaccines to viral infections are associated with the generation of 95 neutralizing antibodies and mimic natural infection (4). The highest titres and affinities of such 96 neutralizing antibodies are generally dependent on CD4 T follicular helper cell (Tfh) interaction with B 97 cells to generate class switching and affinity maturation by somatic hypermutation within germinal 98 centres, in secondary lymphoid organs (5).

99

100 A recent study of the immune response to the mRNA COVID-19 vaccine in SARS-CoV-2 naïve and 101 recovered individuals showed a rapidly induced CD4 T cell response when compared to the gradually 102 developing CD8 T cell response (6). Similarly, when we studied the immune response to vaccinia virus 103 inoculation, highly activated antigen-specific CD4 T cells were often more expanded than 104 corresponding CD8 T cells in blood early in the response (7, 8). Antigen-specific CD4 cytotoxic T 105 lymphocytes (CTL) peaked at day 14, while neutralizing antibodies, and memory CD4 T cells that 106 proliferated in vitro in response to vaccinia antigen appeared later at day 21 (7, 8). The early generation 107 of CD127 (IL-7 receptor alpha chain)-expressing, IL-2-producing, proliferative memory CD4 T cells 108 specific for vaccinia virus is most likely crucial to the long-term protection associated with immunity to 109 smallpox (9). Such T cell proliferation in response to re-exposure to viral antigens is believed to be 110 critical to allow more rapid response to re-infection, after the immune system had returned to 111 homeostasis following contraction of the initial response to the acute infection (reviewed in (10)). 112 Overall, in vitro proliferation of PBMC in response to antigens derived from pathogens is highly 113 correlated with effective immunity (11), due to rapid memory recall response.

114

A number of studies early in the pandemic identified SARS-CoV-2 specific CD4 T cells in COVID-19 patients (*12-16*). However, longer term studies showed a consistent average decline of memory CD4 T

RBD-specific memory CD4 T cells

cells over time with a decrease until 60 days after the acute phase and maintained over 10 months with a central memory phenotype post 6 month (*17*, *18*). Most of these studies have used upregulation of markers of activation on antigen-specific CD4 T cells, similar to the original OX40 assay (*19*). In contrast there is very limited data on proliferative memory SARS-CoV-2-specific CD4 T cells (*17*, *20*).

- While CD4 T cell responses are important for antiviral humoral immunity, CD8 T cells are still believed to be important in cell-mediated immunity to respiratory viruses (*21*). Studies investigating the properties of SARS-CoV-2 reactive CD8 T cells report a high diversity of functional SARS-CoV-2 specific CD8 T cells (*22-24*), with cross-reactivity to seasonal coronavirus antigens (*25*). This indicates that CD8 T cells could be important in viral clearance in individuals that lack neutralizing antibodies (*26*, *27*), although they often display an exhausted phenotype (*22*, *23*).
- 128

In the current study we systematically studied SARS-CoV-2-specific proliferation of CD4 and CD8 T cells in recovered COVID-19 patients to better define the extent of their long-term memory cells. Importantly, RBD-specific proliferative memory CD4 T cells were closely associated with levels of neutralizing antibodies in recovered patients and in vaccinees. Furthermore, single cell RNAseq/TCRseq was used to study the function of individual SARS-CoV-2 reactive CD4 T cells from subjects with high antibody titres.

RBD-specific memory CD4 T cells

136 **RESULTS**

137

138 Proliferative RBD-specific CD4 T cells correlate with neutralising antibody titres

139

140 To assess memory CD4 T cell responses following SARS-CoV-2 infection, we screened 25 ADAPT 141 subjects from the first wave (May-October, 2020; Supplementary Table 1) at 3 months post-infection 142 using recombinant SARS-CoV-2 RBD protein, and using influenza lysate as a control antigen. We utlised our CD25/OX40 (19) assay to assess antigen-specificity of CD4 T cells and found overall a 143 144 13.5-fold higher response to RBD in ADAPT subjects (median 0.46%) at 3 months compared to 145 unexposed controls (n=13; median 0.034%, p < 0.0001) (Figure 1A&B). However, 7/27 ADAPT 146 subjects were negative (<0.2%) for a response to RBD (Figure 1B). All unexposed controls and 147 ADAPT subjects had positive flu specific responses (medians 1.51% and 1.62%, respectively).

148

149 Having seen initial OX40 responses to RBD, we subsequently used the 7-day PBMC proliferation 150 assay with cell trace violet dye (CTV; Supplementary Figure 1) to confirm the presence of memory 151 CD4 T cells. There was no CD4 T cell proliferation response to RBD (< 1% of CD4 T cells) in PBMC 152 from unexposed controls (n=6), while the ADAPT subjects (n=13) had an overall median proliferation 153 of 11.1%, p < 0.01. Again the results were heterogeneous with 6 of the 13 ADAPT subjects tested 154 having < 1 % CD4 T cell proliferation in response to RBD, similar to the unexposed controls in this 155 assay (Figure 1C). Proliferation responses to Flu lysate, by both control and patient PBMC, were all 156 positive, similar to the OX40 results, and generally larger than the responses to SARS-CoV-2 RBD 157 (Figure 1C). There was a highly significant positive correlation between CD25+ OX40+ CD4 T cell 158 responses to RBD and CD4 T cell proliferation responses to RBD (pearsons' rho=0.89, p < 0.0001) 159 (Figure 1D), as we have previously reported for a variety of other recall antigens (19).

160

161 When we compared the levels of anti-spike IgG, measured in the ADAPT subjects' 3-month follow-up 162 serum using the diagnostic DiaSorin Liaison assay, the proliferation of RBD-specific CD4 T cells positively correlated with anti-spike IgG levels (rho=0.52, p < 0.01; Figure 1E). We also used a flow-163 164 based assay (28) to measure spike (Wuhan-1 D614)-specific IgG and IgM in patients' serum samples, 165 which gives scores of 0-3 for each antibody isotype (where 3 is highest). When the IgG and IgM scores 166 were combined, the patients with RBD-specific CD4 T cell reponses had significantly higher antibody 167 levels (median score of 5.5) than patients with negative proliferative responses to RBD (median score 168 of 3, *p*<0.05) (Figure 1F).

RBD-specific memory CD4 T cells

Finally, live virus neutralization assays were performed with the ADAPT patients' sera, measured as an end-point titre (28). The patients with RBD-specific CD4 T cell reponses had significantly higher neutralization titres (NT₅₀, median 256) than patients with negative proliferation results (median 64, p<0.05) (Figure 1G). Collectively these data demonstrate a heterogeneous memory immune response

- 173 observed during natural infection with SARS-CoV-2.
- 174

175 Antibody High versus Antibody Low subject groups

176

177 In order to confirm the association of RBD-specific CD4 T cell responses with higher antibody levels, 178 cryopreserved PBMC and serum samples were studied from an additional 24 ADAPT subjects, 179 separated into two representative groups of 12 subjects each, with known high and low SARS-CoV-2 180 neutralisation titres, respectively, at month 3 (Supplementary Table 1). The selected antibody high (Ab 181 high) subject group had neutralisation titres $NT_{50} \ge 80$, whereas the antibody low (Ab low) group had 182 neutralization titres NT₅₀ \leq 40 (Figure 2A). Neutralisation titres in the Ab high group gradually 183 decreased over time with a median of 320 at 3-month, 240 at 4-month and 120 at 8-month timepoints 184 (Figure 2B). Furthermore, the breadth of neutralizing antibodies to variants of concern was 185 significantly greater in Ab high group at 3-months (Figure 2C), but also then decreased at 8-months 186 (Figure 2D).

187

188 Reduced RBD-specific CD4 T cell responses in indviduals with low antibody levels

189

We also widened our analysis of T cell responses to other SARS-CoV-2 antigens, using peptide pools (Supplementary Table 2), that allowed us to adapt our CD25/OX40 CD4 assay to include the detection of antigen-specific CD8 T cells by adding the co-expression of CD69 and CD137 (4-1BB) surface markers (29).

194

195 RBD-specific CD4 T cells were mostly undetectable in the Ab low group (median 0.12% (3-month) 196 and 0.1% (8-month)), such that the fold difference in RBD-specific CD4 T cell responses between the 2 197 subject groups was 50-fold at month 3 (p<0.001), down to 15-fold at month 8 (p<0.01; Figure 3A). 198 There were also significantly higher CD4 T cell responses to the spike peptide pool in the Ab high 199 subject group compared to the Ab low subject group (Figure 3A), although not as marked as for RBD 190 (above), with a 5.3-fold higher spike-specific response at the 3-month time-point (p<0.01), which was 201 still 3.9-fold higher at 8 months (p<0.01; Figure 3A).

RBD-specific memory CD4 T cells

202

Nucleocapsid protein (NP)-specific CD4 T cell responses were not significantly different between the 2 groups at 3-months, but there was a 15-fold higher frequency in the Ab high subject group compared to the Ab low subject group at 8-months (p<0.01). No difference between the 2 groups was observed in the proportion of antigen-specific CD4 T cells that had a CD39+ Treg phenotype (*30*) (Supplementary Figure 2).

208

209 In addition, we also measured proliferation of CD4 T cells following peptide stimulation and found that 210 there was significantly higher proliferating SARS-CoV-2-reactive CD4 T cells in the Ab high group at 211 both 3- and 8-month timepoints for all 3 peptide pools (Figure 3B). Intracellular phenotyping and 212 dimenisonal reduction utilising UMAP algorithm of spike-specific proliferated CD4 T cells from the 213 Ab high group showed 3 relatively large clusters of Granzyme B+ cells (clusters #3, #7 and #9; Figure 214 3C&D, top row) and relatively few regulatory-like cells expressing Foxp3 (clusters #2 and #4; Figure 215 3C&D, top row). In contrast, proliferated CD4 T cells, in response to the spike peptide pool, from 216 subjects in the Ab low group revealed the greatly increased presence of the 2 clusters of regulatory-like 217 cells expressing Foxp3 (clusters #2 and #4, Figure 3C&D, top row), and greatly reduced Granzyme B+ 218 cells (clusters #3, #7 and #9, Figure 3C&D, top row), compared to the proliferated CD4 T cells from 219 subjects in the Ab high group.

220

Similarly, in RBD-specific proliferated CD4 T cells, the Ab high group had an increased presence of a Granzyme B+Foxp3- cluster (#6; Figure 3C&D middle rows) and less cells in Foxp3+ clusters (#5 and #7; Figure 3C&D middle rows). The opposite was seen in the much smaller proportions of proliferated cells from the Ab low group (Figure 3C&D middle rows). Nucleoprotein-specific proliferated CD4 T cells also showed a very similar trend, with distinct Foxp3+ versus Granzyme B+ clusters between the Ab high and low groups (Figure 3C&D bottom rows).

227

In CD8 T cell specific responses, defined by upregulation of CD137 and CD69, no significant difference was observed between the antibody high or low groups, when stimulated with the 3 SARS-CoV-2 peptide pools or influenza (Figure 4A). However, in proliferation responses, the antibody high group had 4.2-fold higher proliferating NP peptide pool-specific CD8 T cells at 3 months (p<0.01) and 6.6-fold at 8 months (p<0.05), and a trend to higher spike-specific proliferation, compared to the antibody low group (Figure 4B). The much smaller proportions of proliferated CD8 T cells from Ab

RBD-specific memory CD4 T cells

low subjects had clusters with much higher levels of expression of the inhibitory ligand CTLA-4,
compared to proliferated CD8 T cells from Ab high subjects for all 3 peptide pools (Figure 4C&D).

236

B cell plasmablasts, with more CXCR5+ CD4 T cells, and T cell activation are associated with high antibody levels

239

We used 20-parameter flow cytometry to determine ex vivo phenotypic differences in the B and T cell subsets of Ab high and Ab low groups. Higher frequencies of B cell plasmablasts (CD19+IgD-CD27+CD38+) were found in the Ab high group (3.2-fold, p<0.05) at 3 months, but no difference was observed at 8 months (Figure 5A). When CD19+ B cells were divided into memory subsets, there was no difference at either time point for naïve (IgD+CD27-), non-switched memory (IgD+CD27+) or switched memory (IgD-CD27+)(Figure 5B). However, there was higher proportion of double negative (IgD-CD27-) cells in Ab low group at both 3- (1.7-fold, p<0.05) and 8-months (1.6-fold, p<0.05).

247

When surface markers of CD4 T cells were analysed there was significantly increased expression of CXCR5 in the Ab high group at both 3- and 8-month timepoints (2.9-fold, p<0.05 and 2.5-fold, p<0.01, respectively) and co-expressed activation markers HLA-DR+CD38+ (3-fold, p<0.01 and 1.9fold, p<0.01, respectively), compared to the Ab low group (Figure 5C&D). Activated CD8 T cells were also increased at 3-months in Ab high subjects (2.3-fold, p<0.05) but not at 8-months (Figure 5E).

253

Within canonical CD4 T cell subsets, a higher frequency of effector memory cells (Tem; CD45RA-CCR7-) was evident in the Ab high group (1.7-fold, p<0.05 (3-months) and 1.6-fold, p<0.05 (8months), compared to the Ab low group, but no difference was seen in naïve (CD45RA+CCR7+), central memory (Tcm; CD45RA-CCR7+) or memory revertant cells (Temra; CD45RA+CCR7-; Figure 5F). However, naïve (CD45RA+CCR7+) CD8 T cells were significantly higher in the Ab low group (1.8-fold, p<0.05), compared to the Ab high group, at both timepoints (Figure 5G).

260

To ascertain the association between the results of the T cell function assays and antibody levels, Spearman's correlation was performed utilising Benjamini-Hochberg method to correct for multiple comparisons. Positive correlations of antibody levels and neutralization titres were observed with: B cell plasmablasts; CXCR5+ CD4 T cells; CD4 and CD8 T cell activation; and spike- and RBD-specific CD4 T cell recall and proliferative responses. In contrast, DN B cells, naïve CD4 and spike-specific

RBD-specific memory CD4 T cells

266 CD8 recall responses were all negatively correlated with antibodies (Figure 5H). These same 267 parameters were able to separate Ab high and low groups using PCA (Figure 5I).

268

Single-cell RNAseq revealed heterogeneity and TCR diversity in SARS-CoV-2 reactive CD4 T cells

271

272 Our previous observations showed that CD4 T cell recall responses to SARS-CoV-2 positively 273 correlated with greater humoral responses, in particular RBD-specific responses in the Ab high subject 274 group. To better understand these antigen-specific CD4 T cells, especially those specific for RBD, we 275 sorted CD25+CD134+ CD4 T cells from 4 representative subjects from the Ab high group, following 276 stimulation with peptide pools at 44hrs. Unstimulated purified memory CD4 T cells were used as the 277 comparison population (Supplementary Figure 3A&B). Single-cell RNAseq was performed on a total 278 of 14,053 cells comprising: (i) 9,039 ex vivo (unstimulated) memory cells; (ii) 2,026 NP-specific cells; 279 (iii) 1,989 spike-specific cells; and (iv) 999 RBD-specific cells. Analysis of 10x transcriptomics was 280 coupled with TCR α/β sequencing. We found heterogeneous subsets of CD4 T cells that were reactive 281 to spike, RBD and NP; comprising transitional memory, central memory, Treg and cytotoxic subsets 282 (Figure 6 A&B). Enrichment of activated GITR+ Tregs (cluster 3) was particularly evident in the 283 stimulated conditions (48.15%, 62.34% and 54.94% for NP- Spike- RBD-specific cells, respectively), 284 compared to 3.08% for ex vivo memory cells (Figure 6C).

285

286 Analysis of TCR annotation was achieved on 11,824 single cells (84.14%). Diverse TCR responses 287 resulted from all 3 stimulation conditions with similar Shannon Entropy score for the stimulation 288 conditions compared to the unstimulated ex vivo (Supplementary Figure 4A) and diverse TCR α/β 289 pairings for all four conditions (Supplementary Figure 4B). To examine if TCR α/β V gene was altered 290 in the stimulated conditions compared to ex vivo memory, log odds-ratio analysis was performed with 291 Bonferroni's correction. No difference was observed in the majority of TCR α/β V genes between ex 292 vivo memory and stimulated conditions. However, there was increased usage of TCRa TRAV1-293 2/34/39 chains evident in NP-specific CD4 T cells compared to ex vivo memory (Figure 6D), while 294 TRBV10-2 was the only TCR β chain enriched in RBD-specific CD4 T cells (Figure 6E). With the 295 exception of CD4 CTLs, where approximately half of the ex vivo unstimulated clones were re-sampled 296 post-stimulation, generally antigen-specific clonotypes within the ex vivo unstimulated memory cell 297 pool comprised only a tiny fraction of the antigen-specific clonotypes sampled following 2 days of

RBD-specific memory CD4 T cells

antigen stimulation (Figure 6F). Clonotypes shared between unstimulated ex vivo CD4 memory and
 antigen specific pools rarely displayed altered cellular phenotypes following stimulation (Figure 6F).

300301

302 Proliferative CD4 T cell clonotypes are enriched within cytotoxic and Treg subsets

303

To examine the clonal diversity of proliferative CD4 T cell subsets and confirm the single cell RNAseq clonotype data, we performed bulk TCR sequencing on T cells proliferating in response to NP, spike and RBD, compared to an unstimulated control, from the same 4 patients as for the 10X transcriptomics. The TCR clonotypes found to be enriched by proliferation in the stimulated conditions compared to unstimulated were then matched to the same clonotype previously identified via 10X transcriptomics and overlayed on the same UMAP (Figure 7A).

310

311 10% of clonotypes were shared between the single cell RNAseq analysis and the proliferation assay 312 TCR analysis. Enriched proliferative clonotypes identified in the SARS-CoV-2 antigen-stimulated 313 cultures were most frequent in transcriptomic clusters comprising: (i) conventional Granzyme B+ CD4 314 CTL (cluster 2; Figure 7B), (ii) CD4/CD8 double positive CTL (cluster 0; Figure 7B); and (iii) 315 relatively limited proliferation of activated GITR+ Tregs, compared to their identification in the OX40 316 assay 10x only analysis (cluster 3; Figure 7B). The majority of clonotypes identified through the single 317 cell RNAseq analysis were unique singletons, while expanded clonotypes following proliferation consisted mostly of 2 cells with the same clonotype, as well as a small portion of clonotypes that were 318 319 2-5 cells (Figure 7C).

320

As expected, there was very little overlap of TCR clonotypes between the different antigen-specific responses, with <1% of clonotypes being shared (Figure 7D), consistent with high diversity within SARS-COV-2 reactive CD4 T cells. A total of 3, 599 unique SARS-CoV-2 clonotypes were identified in our study that have not been previously reported elsewhere.

325

326 Increased RBD-specific CD4 T cells following vaccination

327

It was then important to assess whether vaccination would improve adaptive immune responses in the low antibody ADAPT convalescent subjects. Between 2 and 4 weeks following the vaccination second dose of either BNT162b2 or ChAdOx1, PBMC samples were collected from the previously infected

RBD-specific memory CD4 T cells

participants, from either the high or low antibody patient groups, respectively. No longitudinal difference was observed between either spike or NP-specific CD4 T cell responses at D2 timepoint (2-4 weeks post-second dose) in both subject groups. However, in RBD-specific responses, in the original Ab low group, there was a 3.4-fold increase from the 8-month convalescent timepoint to the postvaccination D2 timepoint (p<0.01; Figure 8A). No difference was observed in CD8 T cell response between pre or post vaccination timepoints (Figure 8B).

337

338 A sharp increase in neutralizing antibody titres towards the ancestral strain was observed in both Ab 339 high and low groups after vaccination (Ab high 8M NT₅₀=160, D2 NT₅₀=640 [p<0.01]; Ab low 8M 340 NT₅₀=40, D2 NT₅₀=960 [p<0.0001]). Neutralization of the B.1.617.2 delta strain was also increased 341 (Ab high 8M NT₅₀=80, D2 NT₅₀=320 [*p*<0.01]; Ab low 8M NT₅₀=0, D2 NT₅₀=480 [*p*<0.0001]) (Figure 342 8C). As it was previously shown that low RBD-specific CD4 T cells response was associated with low 343 neutralizing antibodies at 3- and 8-months post-infection, it was important to correlate these two 344 parameters at the post-vaccination timepoint. A postive correlation (spearman's rho=0.36, p < 0.05) was 345 observed between RBD-specific CD4 T cells in the OX40 assay and neutralization titre post-second 346 dose (D2) timepoint (Figure 8D).

347

RBD-specific memory CD4 T cells

349 **DISCUSSION**

350

351 This study has revealed that only those convalescent COVID-19 patients who had readily detectable 352 RBD-specific CD4 T cell in vitro recall responses had significantly higher neutralizing antibody titres, 353 whereas lower anti-spike antibody levels, especially neutralizing antibody titres, were associated with a 354 lack of RBD-specific proliferative CD4 T cells. These results raise serious questions of the quality and 355 quantity of any immediate anamnestic in vivo response in patients without these proliferative CD4 T 356 cell responses, if re-exposed to SARS-CoV-2. In contrast, those patients with in vitro proliferative 357 RBD-specific CD4 T cells would be predicted to mount an early vigorous in vivo immune response if 358 re-exposed. Other groups using similar assays to our OX40 assay (12-16) have also found that the 359 majority of recovered COVID-19 patients had detectable responses to pools of spike peptides, but with 360 only a subset of patients having CD4 T cell responses to RBD epitopes. We have also previously 361 shown that early CD4+ T cell responses can predict RBD-specific memory B cell frequencies at 1-year 362 post-infection (31).

363

364 It is widely believed that neutralizing antibodies are the first line of defence against re-infection with 365 the same viral pathogen (4). Our results agree with other studies that there is a very large variation in 366 levels of such neutralizing antibodies in the serum of individuals recovered from COVID-19 (28); the 367 reasons for this range of responses are unknown, but the quantity and quality of viral antigen-specific 368 CD4 T cells are highly likely to be important (5). Furthermore, it is unknown what level of such 369 antibodies are required for complete protection. However, with the current vaccines, and evidence from 370 their Phase III trials, a correlation of higher neutralization titres and lower infection rates has been 371 reported (32).

372

373 Our results directly correlate RBD-specific proliferative CD4 T cell responses in convalescent PBMC 374 with anti-spike antibodies and neutralizing antibody titres. Furthermore, spike-specific CD4 T cells 375 from recovered COVID-19 subjects with low antibody levels showed very little expansion in vitro, and 376 in the smaller number of cells that did proliferate, they appeared to relatively highly express the Treg 377 transcription factor Foxp3. Our CD25/OX40 assay was able to identify SARS-CoV-2-specific Tregs, 378 using CD39 expression (30), which was confirmed at the transcriptional level with Foxp3 and GITR 379 expression. Treg responses have been under-represented in other studies using other activation markers, namely CD40L (CD154) and 4-1BB (CD137) (23, 33-35), together with shorter incubations with 380 381 antigens, that did not pick up these important regulatory cells. Further studies are needed to understand

RBD-specific memory CD4 T cells

whether a preponderance of Tregs exerts a greater influence over a smaller number of spike-specificproliferation-capable CD4 T cells from the Ab low subjects.

384

385 When SARS-CoV-2 spike-, RBD- and NP-specific CD4 T cells from patients from the high Ab group 386 were examined at the single cell transcriptomic level, heterogeneous profiles of CD4 T cell subsets 387 were observed that included central memory cells and CD4 CTL, as well as regulatory T cell 388 populations expressing GITR and Foxp3. Importantly, the specific CD4 and CD8 T cells from patients 389 from the antibody low group showed a predominance of expression of Foxp3 and CTLA-4, 390 respectively, associated with their limited proliferative responses. We have previously reported high 391 CTLA-4 expression in HIV-specific CD4 T cells (36) which was inhibitory to proliferative responses in 392 vitro (37), whereas vaccinia-specific CD4 T cells expressed less CTLA-4 and proliferated well, 21 days 393 after inoculation (7).

394

395 T follicular helpher cells (Tfh) are vital in B cell maturation and immunoglobulin class switching 396 within the germinal centre (5), Two studies have suggested that circulating Tfh (cTfh) from recovered 397 COVID-19 patients include spike-specific CD4 T, but in one study RBD-specific cTfh were rare (12) 398 while in the other, total spike-specific cTfh were only seen in 3/26 subjects (38), overall consistent with 399 a large proportion of immunodominant epitopes for the spike-specific CD4 T cells being outside the 400 RBD (12, 39). Interestingly, one study has reported an immunodominant CD4 epitope within RBD 401 from convalescent PBMC, using in vitro proliferation in response to spike peptides, as an intitial step in 402 a cloning procedure (20), but antibody levels were not reported.

403

404 We were able to characterize in detail the expanded RBD-specific CD4 T cells after in vitro 405 proliferation and, surprisingly, we found no staining for the Tfh-defining transcription factor Bcl6 in 406 the expanded cells from PBMC, despite using staining protocols that readily identified Bcl6+ Tfh and 407 germinal centre B cells in other studies of lymph node (40, 41) and tonsil cells (42). In a previous 408 study, we also identified BCL6 at the single cell level in antigen-specific CD4 T cells in PBMC (43). 409 Therefore, we postulated that spike-specific cTfh cells should be encompassed within the CXCR5+ and 410 activated central memory subsets, observed from our single cell RNAseq data, but low transcript 411 expression of BCL6 did not give us a definitive answer. Nevertheless, future in vitro studies should 412 examine whether memory CD4 T cells in PBMC, in particular cTfh, from recovered COVID-19 413 patients, can boost anti-spike antibodies by memory B cells in vitro, analogous to previous studies for 414 other recall antigens (44). Instead, our analysis of proliferated RBD-specific CD4 T cells showed they

RBD-specific memory CD4 T cells

were more likely to highly express T-bet, the Th1-defining transcription factor. Most studies have reported that IFN- γ is the most prominent cytokine produced by SARS-CoV-2 specific memory T cells in vitro in response to antigen (*12-15*), so expression of T-bet in expanded cells is consistent with a Th1 skewing of spike-specific effector CD4 T cells in PBMC.

419

420 We have previously shown that there are relatively high expression of cytotoxic lymphocyte markers in 421 HIV-specific and CMV-specific CD4 T cells (45-47), as well as CD4 CTL found in other viral 422 infections (reviewed recently in (48)). Very early following vaccinia inoculation, many vaccinia-423 specific CD4 T cells were also CTL, expressing mainly Granzyme K, at day 14, at the same time as the 424 peak of activated CD4 T cells in blood (8), consistent with what was reported for a COVID-19 patient 425 during the acute phase of the infection (49). We identified three transcriptomic clusters of cytotoxic 426 CD4 T cells that were within the SARS-COV-2 reactive subsets by single cell RNAseq. This 427 observation was consistent with our finding of in vitro expanded spike-specific CD4 T cells that 428 expressed protein markers of cytotoxic T lymphocytes (CTL), including the granzymes A and B, and 429 perforin, and cytotoxic granules (as defined by the antibody TIA-1, which recognizes the protein 430 encoded by the gene NKG7 (45, 50)). Highly enriched proliferative clonotypes were also shown to 431 overlap with coventional CD4 CTL and CD4/8 double positive CD4 CTL by single cell RNAseq. It 432 was also evident following bulk TCR-seq that proliferated clonotypes in respone to spike and RBD 433 were enriched within CD4 CTL clusters. Effector CD4 T cells expressing cytotoxic granules have been 434 identified in other single cell transcriptomic studies (35, 51), suggesting that CD4 CTLs may play an 435 important role in eliminating SARS-CoV-2 infected cells.

436

437 Based on what is known about CD4 T cell help for B cell responses (5), it is highly likely that memory 438 CD4 T cells in peripheral blood reflect a large CD4 T cell response in draining lymph nodes, including 439 T follicular helper cells (Tfh), but also resulting in exit of antigen-specific effector and memory cells 440 into the circulation. We have directly observed these highly activated, non-Tfh cells in lymph nodes in 441 untreated HIV-1 infection (40, 42), but their clonal relationship to similarly elevated Tfh cells is still under study. From the current study, it isn't clear at the molecular level why CD4 T cells with 442 443 specificities to epitopes within RBD may generate better levels of anti-spike neutralizing antibodies. Theoretically, any spike-specific CD4 T cells should be able to help B cells that are able to take up 444 445 spike protein via specificity for RBD. However, spike protein is very large and is designed to be 446 cleaved during viral entry into target cells, involving multiple proteases (52-54), so it is possible that 447 spike available for B cell recognition in germinal centres may also be cleaved to smaller protein

RBD-specific memory CD4 T cells

448 fragments, only some of which link B cell and T cell epitopes around RBD. Clearly this needs further 449 study with defined epitopes, along with the clonal relationships between germinal centre Tfh cells 450 during acute infection and memory cells during convalescence. While early studies suggested that there 451 can be intermolecular CD4 help for antibody responses in murine models of influenza infection (55, 452 56), in a vaccinia virus mouse model it was shown clearly that intramolecular CD4 help was required 453 for antibodies to individual viral proteins from this large poxvirus (57). Most studies of SARS-CoV-2 454 specific T cells have used large peptide pools, whereas we have found most of our associations with 455 recombinant proteins which may be an advantage because it requires the full antigen-processing and 456 HLA Class II presentation pathway rather than extracellular saturation with a large number of 457 exogenous peptides. Finally, it also has to be considered whether some RBD epitopes may be obscured 458 by glycan residues that lock the RBD in a "down" position (58), since our recombinant proteins were 459 made in human cell lines.

460

Possible reasons why some infected individuals have low adaptive immune responses could be due to
(i) lower initial viral loads during first wave infections compared to later waves of variants (59); (ii)
antigen presentation to CD4 T cells is dominated by epitopes in spike fragments outside of RBD (39,
60); and (iii) possibly having more inhibitory and/or exhausted B and T cells (23).

465

Importantly, however, it appears that RBD-specific CD4 T cells could be boosted by vaccination. Our
results suggest that booster efficacy would be improved by concentrating on CD4 T cell epitopes in and
around the RBD, which may be the optimal regimen for generation of neutralizing antibodies.

RBD-specific memory CD4 T cells

470 MATERIALS AND METHODS

471

472 ADAPT Cohort

473

474 The ADAPT study is a prospective cohort study of post-COVID-19 recovery established in April 2020 475 (61), with ongoing recruitment (147 participants with confirmed SARS-CoV-2 infection had been 476 enrolled at the time of writing). The majority were recruited following testing in community-based 477 clinics run by St Vincent's Hospital Sydney, with some patients also enrolled with confirmed infection 478 at external sites. Initial study follow-up was planned for 12 months post-COVID-19, and subsequently 479 extended to 2 years. Extensive clinical data was systematically collected, including classification of 480 disease severity, as previously described (61) and a prospective biorepository established, as previously 481 described (62). Subjects classified with mild COVID-19 were those managed in the community with 482 minor, largely upper respiratory tract viral symptoms, including pharyngitis, rhinorrhea, headache, and 483 anosmia/ageusia. Subjects with moderate COVID-19 were managed in the community with fever/chills 484 and one of the following organ-localizing symptoms, or at least two of the following organ-localizing 485 symptoms: cough, hemoptysis, shortness of breath, chest pain, nausea/vomiting, diarrhea, altered 486 consciousness/confusion. Subjects with severe COVID-19 were those who required inpatient care 487 (wards or intensive care unit), as previously described (61). Laboratory testing for SARS-CoV-2 was performed using nucleic acid detection from respiratory specimens with the EasyScreen[™] SARS-CoV-488 489 2 Detection kit (Genetic Signatures, Sydney, Australia). Enrolment visits were performed at median 76 490 (IQR 64-93) days after initial infection (3-months) and 8-month assessments were performed at median 491 232 (IQR 226-253) days after initial infection. Serum and PBMCs were collected from ADAPT study 492 participants following vaccination with either 2 doses of BNT162b2 (Pfizer) or ChAdOx1 493 (AstraZeneca).

The demographics of the ADAPT study participants in this report (first wave patients, recruited prior to October, 2020) are shown in Supplementary Table 1. Unexposed healthy adult donors (n=13; 45% male; median age 46) were recruited through St Vincent's Hospital, were anti-spike antibody negative, and tested prior to vaccination.

- 498
- 499 Ethics
- 500

501 The ADAPT study was approved by the St Vincent's Hospital Human Research Ethics Committee 502 (2020/ETH00964) and is a registered trial (ACTRN12620000554965). ADAPT-C sub study was

RBD-specific memory CD4 T cells

503 approved by the same committee (2020/ETH01429). All data were stored using REDCap electronic 504 data capture tools. Unexposed healthy adult donors were recruited through St Vincent's Hospital which

- 505 was approved by St Vincent's Hospital Human Research Ethics Committee (HREC/13/SVH/145 and
- 506 HREC/10/SVH/130). All participants gave written informed consent.
- 507

508 Antigens

509

510 Recombinant SARS-CoV-2 RBD polypeptide was produced using DNA encoding a His-tagged 200 511 amino acid region, for residues 319 to 541 of SARS-CoV-2 S protein, as previously described (63), 512 corresponding to the following amino acid sequence: RV OPTESIVRFP NITNLCPFGE 513 VFNATRFASV YAWNRKRISN CVADYSVLYN SASFSTFKCY GVSPTKLNDL CFTNVYADSF 514 VIRGDEVRQI APGQTGKIAD YNYKLPDDFT GCVIAWNSNN LDSKVGGNYN YLYRLFRKSN 515 LKPFERDIST EIYQAGSTPC NGVEGFNCYF PLQSYGFQPT NGVGYQPYRV VVLSFELLHA 516 PATVCGPKKS TNLVKNKCVN FG SHHHHHH, which was cloned into pCEP4 vector (Thermo 517 Fisher) and expressed transiently in Expi293 cells (Thermo Fisher) using the Expifectamine 518 transfection kit (Thermo Fisher). After 7 days of expression, the culture supernatant was filtered, 519 dialysed against PBS and the protein purified using the His-tag and Talon resin (Thermo Fisher), as 520 previously described (63).

521 Recombinant trimeric SARS-CoV-2 spike protein was expressed from a plasmid encoding the spike 522 protein with C-terminal trimerization domain and His tag which was a gift from the Krammer lab (BEI 523 Resources, NIAID, NIH). The plasmid was transfected into Expi293 cells and protein expressed for 3 524 days at 37°C, 5% CO2. The protein was purified using the His tag as for the RBD purification. The 525 protein was further purified on a Superose 6 gel filtration column (GE Healthcare) using an AKTA 526 Pure FPLC instrument (GE Healthcare) to isolate the trimeric protein and remove S2 pre-fusion 527 protein, as previously described (63). Pools of 15-mer peptides corresponding to the sequence of 528 SARS-CoV-2 spike protein were purchased from Genscript (Hong Kong) and are listed in 529 Supplementary Table 2. His-tagged purified recombinant spike proteins from human coronavirus 530 strains 229E, NL63 and OC43 were purchased from SinoBiologicals US (Wayne, PA, USA). Anti-531 CD3/anti-CD28/anti-CD2 polyclonal T cell activator was purchased from StemCell Technologies 532 (Vancouver, Canada). Purified Influenza A (A/Sydney/5/97) was a gift from Alan Hampson, CSL, as 533 previously described (19).

534

535 CD25/OX40 assay

RBD-specific memory CD4 T cells

536

537 Peripheral blood mononuclear cells (PBMC) were isolated from EDTA anti-coagulated blood within 4 538 hr of venepuncture, as previously described (8). Antigen-specific CD4 T cells responding to recall 539 antigens, simultaneously up-regulating CD25 and CD134 (OX40), were measured in cultures of 540 300,000 PBMC in 200 µl/well of a 96-well plate, in Iscove's Modified Dulbecco's Medium (IMDM; 541 Thermofisher, Waltham, MA, USA) containing 10% human serum (kind gift, Dr Wayne Dyer, 542 Australian Red Cross Lifeblood, Sydney, Australia), which were incubated for 44-48 hr, in a 5% CO₂ 543 humidified incubator, as previously described (19). Separate cultures were incubated with individual 544 SARS-CoV-2 antigens as indicated. All experiments additionally included: (i) a culture medium only, 545 negative control well; (ii) anti-CD3/anti-CD28/anti-CD2 T cell activator (1/200 dilution), polyclonal 546 positive control well; and (iii) influenza virus (1/200 dilution), antigen positive control well. PBMC 547 from the respective cultures were stained with CD3-PerCP-Cy5.5, CD4-FITC, CD25-APC, and 548 CD134-PE (BD Biosciences, San Jose, CA, USA) and run on a 5-laser Fortessa X20 (BD Biosciences) 549 as previously described (64). Antigen-specific CD4 T cells were gated and expressed as 550 CD25+CD134+ % of CD4+ CD3+ T cells as previously described (19). Cultures were classified as 551 positive for antigen-specific CD4 T cells if the CD25+CD134+ % of CD4+ CD3+ T cells was $\geq 0.2\%$ 552 (65).

553

554 Cell Trace Violet (CTV) proliferation assays

555

556 PBMC were resuspended at a concentration of 10 x 10^6 /ml in PBS and incubated with Cell Trace 557 Violet (CTV) dye (Thermofisher) at 5 µM for 20 min at RT, according to the manufacturer's 558 directions. Cells were washed once with 5x volume of IMDM/10% human serum and resuspended for 559 cultures of 300,000 PBMC in 200 µl/well of a 96-well plate and incubated for 7 days in a 5% CO₂ 560 incubator. Different wells contained different antigens as indicated. All experiments also included: (i) 561 culture medium only negative control well; (ii) anti-CD3/anti-CD28/anti-CD2 T cell activator (1/200 562 dilution) polyclonal positive control well; and (iii) influenza virus (1/200 dilution) antigen positive 563 control well. After 7 days, cells from the respective cultures were stained with CD3-PerCP-Cy5.5, CD4-FITC, CD8-APC-H7 and CD25-APC (BD Biosciences), and analysed on a 5-laser Fortessa X20 564 (64) and antigen-specific CD4 T cells gated as CD3+CD4+CD25^{high}CTV^{dim} as previously described 565 (66). Cultures were classified as positive for antigen-specific CD4 T cells if the CD25^{high}CTV^{dim} % of 566 567 CD4+ CD3+ T cells was $\geq 1\%$.

RBD-specific memory CD4 T cells

569 Intracellular analysis of transcription factors

570

571 Expanded CD25^{high}CTV^{dim} antigen-specific CD4+ CD3+ T cells at the end of a 5 day incubation period 572 were analysed for expression of intracellular markers including transcription factors, cytotoxic effector 573 molecules and CTLA-4 using Transcription Buffer permeabilization reagents (BD Biosciences), 574 according to the manufacturer's directions. The monoclonal antibodies used were: Tbet-BV711 575 (BioLegend); RORgT-PE and CTLA-4-PECy5 (BD Bioscences); Eomes-PE-Cy7, Bcl6-PerCP-eFluor 576 701 and Foxp3-AF700 (eBiosciences, Thermofisher). Following intracellular staining, cells were 577 resuspended in 1% paraformaldehyde/PBS and analysed on the 5-laser Fortessa X20.

578

579 Ex vivo phenotyping and combined CD4/CD8 T cell activation assay

580

581 Cryopreserved PBMCs were thawed using RPMI medium containing L-glutamine and 10% FCS 582 (ThermoFisher Scientific, USA) supplemented with Penicillin/Streptomycin (Sigma-Aldrich, USW), 583 and subsequently stained with antibodies binding to extracellular markers. Extracellular panel included: 584 Live/Dead dye Near InfraRed, CXCR5 (MU5UBEE), CD38 (HIT2) (ThermoFisher Scientific, USA); 585 CD3 (UCHT1), CD8 (HIL-72021), PD-1 (EH12.1), TIM-3 (TD3), CD27 (L128), CD45RA (HI100), 586 IgD (IA6-2), CD25 (2A3), and CD19 (HIB19) (BioLegend, USA); CD4 (OKT4), CD127 (A019D5), 587 HLA-DR (L234), GRP56 (191B8), CCR7 (G043H7) and CD57 (QA17A04) (BD Biosciences, USA). 588 FACS Perm Buffer II (BD Pharmingen) was used for intracellular staining of granzyme B (GB11, BD 589 Biosciences). FACS staining of 48hr activated PBMCs was performed as described previously, but 590 with the addition of CD137 (4B4-1) to the cultures at 24hrs. Final concentration of 10µg/mL of SARS-591 CoV-2 peptide pools (Genscript) were used, 1 µg/mL of Influvac tetra influenza vaccine (Mylan 592 Health, Sydney, Australia) was used as a control antigen and staphylococcal enterotoxin B (SEB; 1 593 µg/ml) was used as a positive control (Thermo Fisher Scientific). In vitro activation mAb panel 594 included: CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD39 (A1), CD69 (FN50) all BioLegend, 595 CD25 (2A3), CD134 (L106)- BD Biosciences. Samples were acquired on the Aurora CS spectral flow 596 cytometer (Cytek Biosciences, USA) using the Spectroflo software. Prior to each run, all samples were 597 fixed in 0.5% paraformaldehyde. Data analysis was performed using FlowJo version 10.7.1 (TreeStar).

598

599 Anti-Spike diagnostic serology

RBD-specific memory CD4 T cells

- 601 Antibodies to SARS-CoV-2 spike in serum samples from ADAPT subjects were measured using the
- 602 LIAISON® SARS-CoV-2 S1/S2 IgG diagnostic assay (Diasorin, Saluggia, Italy), according to the
- 603 manufacturer's direction. This method quantitatively detects IgG anti-S1 and anti-S2 specific
- antibodies by indirect chemiluminescence immunoassay, using recombinant S1 and S2 antigens.
- 605

606 Flow cytometry based IgG/IgM serology

607

608 The assay to detect patient serum antibodies against SARS-CoV-2 antigens using flow cytometry has 609 been previously described in detail (28). Briefly, HEK293 cells were transfected to transiently express 610 SARS-CoV-2 full-length Spike (Wuhan-1 D614), Membrane and Envelope proteins. Diluted patient 611 serum was added to the cells, followed by adding AlexaFluor 647-conjugated anti-human IgG (H+L) 612 (Thermo Fisher Scientific) or anti-human IgM (A21249, Thermo Fisher Scientific). The LSRII flow 613 cytometer (BD Biosciences, USA) was used to acquire the cells and patients were confirmed SARS-614 CoV-2 antibody positive if, in at least two of three quality-controlled experiments, their median 615 fluorescence intensity ($\Delta MFI \square = \square MFI$ transfected cells – MFI untransfected cells) was above the 616 positive threshold (mean Δ MFI + 4SD of 24 pre-pandemic controls). Data were analysed using FlowJo 617 10.4.1 (TreeStar, USA), Excel (Microsoft, USA), and GraphPad Prism (GraphPad Software, USA).

618

619 Live virus neutralization assay

620

621 HEK293T cells were transduced with lentiviral particles to stably express human ACE2 and 622 TMPRSS2. Briefly, the lentiviral expression vectors pRRLsinPPT.CMV.GFP.WPRE (Follenzi et al., 623 2002) and pLVX-IRES-ZsGreen (Clontech) were used to clone the ORFs for hACE2 (Addgene#1786) 624 and hTMPRSS2a (Addgene#53887, synthetic gene fragment; IDT), respectively. Lentiviral particles for 625 transduction, to express the above proteins, were produced by co-transfecting the second generation 626 lentiviral packaging constructs psPAX2 (courtesy of Dr Didier Trono through NIH AIDS repository) 627 and VSVG plasmid pMD2.G (Addgene#2259) and the expression plasmids individually in HEK293T 628 cells (Life Technologies) using polyethyleneimine, as previously described (67). To generate the 629 HEK293/ACE2/TMPRSS2a cells, two successive rounds of lentiviral transductions were performed; 630 the highly permissive clone, HekAT24 was identified by clonal selection and then used to carry out the 631 SARS-CoV-2 neutralisation assay as previously described (67).

RBD-specific memory CD4 T cells

633 To perform the assay, HekAT24 cells were trypsinized and while in suspension stained with Hoechst-634 33342 dye (5% v/v) (NucBlue, Invitrogen) and then seeded in a 384-well plate (Corning #CLS3985) at 635 16,000 cells per well in 40µL of DMEM-5% FCS. Patient plasma samples were mixed at two-fold dilutions with an equal volume of SARS-CoV-2 virus solution (4 \times 10³ TCID₅₀/ml). Following 636 incubation at 37° C for 1 hour, 40μ L were transferred in duplicate to the cells (final MOI = 0.05). The 637 638 following variants of concern were included as viral variants: Beta (B.1.351), Gamma (P.1), Delta 639 (B.1.617), as well as control virus from the same clade with matching 'D614G' background (B1.319). 640 Following 24 hours of incubation, entire wells were imaged by high-content fluorescence microscopy 641 and an automated image analysis software obtained the cell counts. The following formula was used to 642 calculate the percentage of virus neutralisation: %N = (D-(1-O)) × 100/D, where O = nuclei count 643 normalized to mock controls and D = 1-Q for average of infection controls as previously described 644 (67). Neutralisation activity, NT_{50} was defined as the serum dilution that led to 50% neutralization of 645 infection.

646

647 Dimensional Reduction and Clustering Analysis

648 FCS3.0 files were compensated manually using acquisition-defined matrix as a guide, and gating 649 strategy was based on unstained or endogenous controls. Live singlets were gated from proliferated 650 CD25+CTV- CD4+, or CD8+, respectively, CD3+ T cells using FlowJo v.10.7.2, samples were decoded and statistical analysis between groups and unsupervised analysis was performed. For 651 652 unsupervised analysis, the following FlowJo plugins were used: DownSample (v.3), UMAP (v.0.2), 653 Phenograph (v.3.0) and ClusterExplorer (v.1.5.9) (all FlowJo LLC). Equal number of events for each 654 condition were taken from each grouped sample by down sampling. The two new FCS files corresponding to Ab high and Ab low were then concatenated for dimensionality reduction analysis 655 656 using UMAP. UMAP was conducted using the following parameters for proliferated CD4 T cells: T-657 bet, Eomes, Granzyme B, Foxp3, RORyt, and BCL-6; and for CD8+ T cells: T-bet, Eomes, Granzyme 658 B and CTLA-4. The Phenograph plugin was then used to determine clusters of phenotypically related 659 cells. The same markers as TriMap and parameters k = 152 and Run ID = auto was used for analysis. 660 Finally, ClusterExplorer plugin was used to identify the phenotype of the clusters generated by 661 Phenograph.

662 Single cell RNA-seq analysis of antigen-specific T cells

RBD-specific memory CD4 T cells

664 PBMC from 4 Ab high donors were cultured for 48 hr with NP, spike and RBD peptide pools, respectively (Supplementary Table 2), as for the OX40 assays (see above). A total of 14,053 SARS-665 COV-2 specific CD25+OX40+ CD4 T cells from these cultures were purified using FACSAriaIII cell 666 667 sorter (BD biosciences), as shown in Supplementary Fig 2A. Unstimulated purified CD45RO+ ex vivo 668 memory CD4 T cells were used as a comparator subset (Supplementary Fig 2B). Purity of sorted 669 populations were >99%. Populations were individually stained with Total-Seq C hashtags (BioLegend), 670 and single cell libraries were generated using the 5'v2 Gene expression and immune profiling kit (10x 671 Genomics). Subsequent cDNA and TCR libraries were generated according to manufacturer's 672 instructions. Generated libraries were sequenced on the NovaSeq S4 flow cell (Illumina) at Read 1 =673 28, i7 index = 10, i5 index = 10 and Read 2 = 90 cycles according to manufacturer's instructions.

674

675 Transcriptomic analysis

676

677 Pre-processing of raw sequencing files

678 Single-cell sequencing data was aligned and quantified using Cell Ranger (10x Genomics) against the 679 human reference genome (10x Genomics, July 7, 2020 release) with default parameters. Raw hashtag data was processed using CITE-Seq count algorithm (68). Cell conditions were demultiplexed using 680 681 'HTODemux' function implemented in Seurat (68). Filtering and quality control was performed using Seurat (69) on data containing 15,276 cells where 14,053 cells were retained satisfying thresholds of 682 683 both <10% mitochondria content and number of genes between 300 and 5000. 'SCTransform' was 684 used for normalization (70). Genes encoding BCR and TCR were removed to improve cell clustering. Principal Component Analysis (PCA) dimensional reduction was performed on variable genes 685 686 identified by 'VariableFeatures' function and cell clusters were visualised using Uniform Manifold 687 Approximation and Projection (UMAP) clustering implemented in Seurat (69).

688

689 Annotation of cell identities and Differential gene expression analysis

690

T cell sub-populations were manually annotated based on UMAP clustering and markers defined by'FindAllMarkers' function in Seurat.

Raw counts from defined cell populations were normalised using scran / scater (71, 72) and differential gene expression analysis was performed using Limma voom (73).

695

696 TCR analysis of bulk proliferated cells

RBD-specific memory CD4 T cells

697 RNA was extracted from bulk proliferated cultures using RNAeasy micro kit (Qiagen) as per 698 manufacturer's instructions. TCR high throughput RNA sequencing methods have been previously 699 published in detail (74). Briefly, reverse transcription of RNA was performed using a modified 700 SmartSeq2 protocol that incorporated a 10bp universal molecular identifiers (UMI) into cDNA 701 molecules. The first round of PCR was performed using primers against adapter sequences 702 incorporated during cDNA synthesis with 1x KAPA HiFI HotStart ReadyMix and 8.3 mM Fwd and 703 Rev primer with the following conditions: 98°C for 3 min; [98°C for 20 s, 67°C for 15 s, 72°C for 6 704 min] x 10 cycles; 72°C for 5 min. Purified PCR products were used in a second PCR targeting the 705 TCRβ chain under the following conditions: 98°C for 45 s; [98°C for 15 s, 60°C for 30 s, 72°C for 30 706 s] x 30 cycles; 72°C for 1 min. Purified PCR products were then barcoded using the Nextera Index kit 707 to enable pooling of multiple samples and sequenced on an Illumina MiSeq at 300bp paired-end reads 708 to a depth of ~0.5 million read pairs per sample. Primer sequences were as previously described (74).

709 Analysis of single cell and bulk TCR datasets

710

711 Bulk TCRB datasets for the proliferation assay were processed with the Presto package (version 0.7.0 712 2021.10.28) (75). Reads were filtered for a minimum quality score of 20 using FilterSeq. R2s were 713 trimmed of the TRC primer using MaskPrimers requiring exact primer matches. MaskPrimers was also 714 used to extract the 10 nucleotide UMIs from R1 and to trim to TSO sequences. Trimmed R1 and R2 715 were paired with PairSeq and consensus UMIs were defined with BuildConsensus. R1 and R2 were 716 then merged with AssemblePairs and the dataset was dereplicated to unique sequences and converted 717 from fastq to fastq with CollapseSeq. Sequences with ambiguous bases (n) were discarded. 718 Dereplicated fasta datasets were aligned against the IMGT human TCR reference directory 719 [https://www.imgt.org/vquest/refseqh.html, downloaded 16-Jan-2020] using IgBLAST (76) via 720 AssignGenes to generated AIRR formatted output.

721

To ensure consistent gene calling, TCR contigs from 10x's cellranger vdj were re-aligned to the IMGT human TCR reference set with AssignGenes from the Presto package. Change-o databases were generated with MakeDb and subset to TCRA and TCRB with ParseDb from the Change-o package (version 1.2.0 2021.10.29) (77).

726

TCR clonotypes were defined using the TCRV, TCRJ and CDR3 AA sequence. Clonotype information
 from 10x VDJ was integrated with the 10x scRNA-seq within the Seurat package (version 4.1.0) (78)

RBD-specific memory CD4 T cells

in R [R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/] using RStudio [RStudio Team (2021). RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA URL http://www.rstudio.com/] based on shared cell barcodes. For the proliferation assay bulk sequencing, enrichment was calculated by comparing clonotype UMI counts in stimulation conditions versus baseline/unstimulated with a pseudocount of 1 for clonotypes that were absent from the baseline sampling. Proliferation assay data was merged with the 10x data based on shared TCRB clonotypes.

736

TCR repertoires were explored using the tidyverse package (79) to aggregate and summarise data.
Diversity was calculated as Shannon's Entropy (80) as implemented by the entropart package (81).
Repertoire features were visualised with ggven [https://CRAN.R-project.org/package=ggvenn], circos
(82), ggpubr [https://CRAN.R-project.org/package=ggpubr] and ggsci [https://CRAN.Rproject.org/package=ggsci].

742

To annotate previously reported SARS-CoV-2 specific T cells, TCRBs reported to bind SARS-CoV-2 epitopes were obtained from two public resources; immuneCODE MIRA (release 002.2) (*83*) and VDJdb (v2021-09-05) (*84*). TCRB clonotype labels were reformatted for consistency and clonotypes were annotated based on shared clonotype labels between the databases and dataset.

747

748 Statistical Analysis

749

All column graphs are presented as medians with inter-quartile ranges. Mann-Whitney non-parametric test was used to compare unpaired groups and Pearsons' correlation was used to analyse statistical relationships between continuous variables, employing Prism 9.0 software (GraphPad, La Jolla, CA, USA). RStudio version 1.2.1335 was used to generate PCA graphs. *p* values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001, and ****<0.0001).

755

756 Data availability

757

Single-cell RNA transcriptomic and TCR sequences including codes and raw data has been deposited
to NCBI GEO database, accession number GSE198281. Novel SARS-CoV-2 specific TCR sequences
described in our study will be deposited into VdJdB database.

RBD-specific memory CD4 T cells

762 SUPPLEMENTARY DATA

- 763
- 764 Supplementary Table 1 ADAPT study patient characteristics. Age, gender, ethnicity, and severity at
- 765 month 3 and 8 post-infection.
- 766 Supplementary Table 2 Peptide pools: SN (spike non-RBD), SR (spike RBD), NP (Nucleocapsid
- 767 protein).
- 768 Supplementary Figure 1 Cell trace violet (CTV) 7-day proliferation assay.
- 769 Supplementary Figure 2 CD39+ antigen-specific Treg responses.
- 770 Supplementary Figure 3 Cell sorting for single-cell transcriptomics.
- 771 Supplementary Figure 4 Diversity of SARS-CoV-2 specific TCR clonotypes.

RBD-specific memory CD4 T cells

772 **REFERENCES**

- C. H. Hansen, D. Michlmayr, S. M. Gubbels, K. Mølbak, S. Ethelberg, Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet* **397**, 1204-1212 (2021).
- H. N. Altarawneh, H. Chemaitelly, M. R. Hasan, H. H. Ayoub, S. Qassim, S. AlMukdad, P.
 Coyle, H. M. Yassine, H. A. Al-Khatib, F. M. Benslimane, Z. Al-Kanaani, E. Al-Kuwari, A.
 Jeremijenko, A. H. Kaleeckal, A. N. Latif, R. M. Shaik, H. F. Abdul-Rahim, G. K. Nasrallah,
- M. G. Al-Kuwari, A. A. Butt, H. E. Al-Romaihi, M. H. Al-Thani, A. Al-Khal, R. Bertollini, P.
 Tang, L. J. Abu-Raddad, Protection against the Omicron Variant from Previous SARS-CoV-2
 Infection. *New England Journal of Medicine* 386, 1288-1290 (2022).
- A. Fontanet, S. Cauchemez, COVID-19 herd immunity: where are we? *Nat Rev Immunol*, (2020).
- 785 4. G. J. Nabel, Designing tomorrow's vaccines. *N Engl J Med* **368**, 551-560 (2013).
- 5. S. Crotty, Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29, 621-663 (2011).
- M. M. Painter, D. Mathew, R. R. Goel, S. A. Apostolidis, A. Pattekar, O. Kuthuru, A. E.
 Baxter, R. S. Herati, D. A. Oldridge, S. Gouma, P. Hicks, S. Dysinger, K. A. Lundgreen, L.
 Kuri-Cervantes, S. Adamski, A. Hicks, S. Korte, J. R. Giles, M. E. Weirick, C. M. McAllister,
 J. Dougherty, S. Long, K. D'Andrea, J. T. Hamilton, M. R. Betts, P. Bates, S. E. Hensley, A.
 Grifoni, D. Weiskopf, A. Sette, A. R. Greenplate, E. J. Wherry, Rapid induction of antigen-
- recific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS CoV-2 mRNA vaccination. *Immunity* 54, 2133-2142 e2133 (2021).
- 7. J. J. Zaunders, W. B. Dyer, M. L. Munier, S. Ip, J. Liu, E. Amyes, W. Rawlinson, R. De Rose,
 7. S. J. Kent, J. S. Sullivan, D. A. Cooper, A. D. Kelleher, CD127+CCR5+CD38+++ CD4+ Th1
 7. effector cells are an early component of the primary immune response to vaccinia virus and
 7. precede development of interleukin-2+ memory CD4+ T cells. *J Virol* 80, 10151-10161 (2006).
- C. M. Munier, D. van Bockel, M. Bailey, S. Ip, Y. Xu, S. Alcantara, S. M. Liu, G. Denyer, W.
 Kaplan, P. S. group, K. Suzuki, N. Croft, A. Purcell, D. Tscharke, D. A. Cooper, S. J. Kent, J. J.
 Zaunders, A. D. Kelleher, The primary immune response to Vaccinia virus vaccination includes
 cells with a distinct cytotoxic effector CD4 T-cell phenotype. *Vaccine* 34, 5251-5261 (2016).
- 802 9. E. Hammarlund, M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M.
 803 Hanifin, M. K. Slifka, Duration of antiviral immunity after smallpox vaccination. *Nat Med* 9, 1131-1137 (2003).
- P. C. Doherty, J. P. Christensen, Accessing complexity: the dynamics of virus-specific T cell
 responses. *Annu Rev Immunol* 18, 561-592 (2000).
- I. J. Zaunders, D. van Bockel, Innate and Adaptive Immunity in Long-Term Non-Progression in
 HIV Disease. *Front Immunol* 4, 95 (2013).
- J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R. Esterbauer, H. E.
 Kent, C. J. Batten, F. L. Mordant, N. A. Gherardin, P. Pymm, M. H. Dietrich, N. E. Scott, W.
 H. Tham, D. I. Godfrey, K. Subbarao, M. P. Davenport, S. J. Kent, A. K. Wheatley, Humoral
 and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nat Med* 26, 1428-1434 (2020).
- 814 13. A. Grifoni, D. Weiskopf, S. I. Ramirez, J. Mateus, J. M. Dan, C. R. Moderbacher, S. A.
- 815 Rawlings, A. Sutherland, L. Premkumar, R. S. Jadi, D. Marrama, A. M. de Silva, A. Frazier, A.
- 816 F. Carlin, J. A. Greenbaum, B. Peters, F. Krammer, D. M. Smith, S. Crotty, A. Sette, Targets of
- 817 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
- 818 Unexposed Individuals. *Cell* **181**, 1489-1501 e1415 (2020).
- L. Ni, F. Ye, M. L. Cheng, Y. Feng, Y. Q. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L. Sun,
 T. Cao, P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, C. F. Qin, F. Chen, C. Dong,

- Betection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
 Convalescent Individuals. *Immunity* 52, 971-977 e973 (2020).
- 15. D. Weiskopf, K. S. Schmitz, M. P. Raadsen, A. Grifoni, N. M. A. Okba, H. Endeman, J. P. C.
 van den Akker, R. Molenkamp, M. P. G. Koopmans, E. C. M. van Gorp, B. L. Haagmans, R. L.
 de Swart, A. Sette, R. D. de Vries, Phenotype and kinetics of SARS-CoV-2-specific T cells in
 COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol* 5, (2020).
- 827 16. J. Braun, L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M.
- 828 Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold, L. Henze, R. Lauster, M. A. Mall,
- K. Beyer, J. Rohmel, S. Voigt, J. Schmitz, S. Miltenyi, I. Demuth, M. A. Muller, A. Hocke, M.
 Witzenrath, N. Suttorp, F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V. M. Corman, C.
 Giesecke-Thiel, L. E. Sander, A. Thiel, SARS-CoV-2-reactive T cells in healthy donors and
- patients with COVID-19. *Nature*, (2020).
- J. H. Jung, M. S. Rha, M. Sa, H. K. Choi, J. H. Jeon, H. Seok, D. W. Park, S. H. Park, H. W.
 Jeong, W. S. Choi, E. C. Shin, SARS-CoV-2-specific T cell memory is sustained in COVID-19
 convalescent patients for 10 months with successful development of stem cell-like memory T *Nat Commun* 12, 4043 (2021).
- I. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I. Ramirez, S.
 Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F. Krammer, V. Simon,
 E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette, S. Crotty, Immunological memory to
 SARS-CoV-2 assessed for up to eight months after infection. *bioRxiv*, (2020).
- I. J. Zaunders, M. L. Munier, N. Seddiki, S. Pett, S. Ip, M. Bailey, Y. Xu, K. Brown, W. B.
 Dyer, M. Kim, R. de Rose, S. J. Kent, L. Jiang, S. N. Breit, S. Emery, A. L. Cunningham, D. A.
 Cooper, A. D. Kelleher, High levels of human antigen-specific CD4+ T cells in peripheral
 blood revealed by stimulated coexpression of CD25 and CD134 (OX40). *J Immunol* 183, 28272836 (2009).
- J. S. Low, D. Vaqueirinho, F. Mele, M. Foglierini, J. Jerak, M. Perotti, D. Jarrossay, S. Jovic, L.
 Perez, R. Cacciatore, T. Terrot, A. F. Pellanda, M. Biggiogero, C. Garzoni, P. Ferrari, A.
 Ceschi, A. Lanzavecchia, F. Sallusto, A. Cassotta, Clonal analysis of immunodominance and
 cross-reactivity of the CD4 T cell response to SARS-CoV-2. *Science* **372**, 1336-1341 (2021).
- M. E. Schmidt, S. M. Varga, The CD8 T Cell Response to Respiratory Virus Infections. *Front Immunol* 9, 678 (2018).
- M. S. Rha, E. C. Shin, Activation or exhaustion of CD8(+) T cells in patients with COVID-19. *Cell Mol Immunol* 18, 2325-2333 (2021).
- A. Kusnadi, C. Ramirez-Suastegui, V. Fajardo, S. J. Chee, B. J. Meckiff, H. Simon, E. Pelosi,
 G. Seumois, F. Ay, P. Vijayanand, C. H. Ottensmeier, Severely ill COVID-19 patients display
 impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells. *Sci Immunol* 6, (2021).
- E. Gimenez, E. Albert, I. Torres, M. J. Remigia, M. J. Alcaraz, M. J. Galindo, M. L. Blasco, C.
 Solano, M. J. Forner, J. Redon, J. Signes-Costa, D. Navarro, SARS-CoV-2-reactive interferongamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019. *J Med Virol* 93, 375-382 (2021).
- K. E. Lineburg, E. J. Grant, S. Swaminathan, D. S. M. Chatzileontiadou, C. Szeto, H. Sloane,
 A. Panikkar, J. Raju, P. Crooks, S. Rehan, A. T. Nguyen, L. Lekieffre, M. A. Neller, Z. W. M.
 Tong, D. Jayasinghe, K. Y. Chew, C. A. Lobos, H. Halim, J. M. Burrows, A. Riboldi-
- Tong, D. Jayasinghe, K. Y. Chew, C. A. Lobos, H. Halim, J. M. Burrows, A. RiboldiTunnicliffe, W. Chen, L. D'Orsogna, R. Khanna, K. R. Short, C. Smith, S. Gras, CD8(+) T cells
- runnenne, w. chen, L. D'Orsogna, K. Khanna, K. K. Short, C. Shifti, S. Gras, CD8(+) T cens
 specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective
 seasonal coronaviruses. *Immunity* 54, 1055-1065 e1055 (2021).
- 26. I. Schulien, J. Kemming, V. Oberhardt, K. Wild, L. M. Seidel, S. Killmer, Sagar, F. Daul, M.
 Salvat Lago, A. Decker, H. Luxenburger, B. Binder, D. Bettinger, O. Sogukpinar, S. Rieg, M.
 Panning, D. Huzly, M. Schwemmle, G. Kochs, C. F. Waller, A. Nieters, D. Duerschmied, F.

870		Emmerich, H. E. Mei, A. R. Schulz, S. Llewellyn-Lacey, D. A. Price, T. Boettler, B. Bengsch,
871		R. Thimme, M. Hofmann, C. Neumann-Haefelin, Characterization of pre-existing and induced
872		SARS-CoV-2-specific CD8(+) T cells. <i>Nat Med</i> 27, 78-85 (2021).
873	27.	T. H. O. Nguyen, L. C. Rowntree, J. Petersen, B. Y. Chua, L. Hensen, L. Kedzierski, C. E. van
874		de Sandt, P. Chaurasia, H. X. Tan, J. R. Habel, W. Zhang, L. F. Allen, L. Earnest, K. Y. Mak, J.
875		A. Juno, K. Wragg, F. L. Mordant, F. Amanat, F. Krammer, N. A. Mifsud, D. L. Doolan, K. L.
876		Flanagan, S. Sonda, J. Kaur, L. M. Wakim, G. P. Westall, F. James, E. Mouhtouris, C. L.
877		Gordon, N. E. Holmes, O. C. Smibert, J. A. Trubiano, A. C. Cheng, P. Harcourt, P. Clifton, J.
878		C. Crawford, P. G. Thomas, A. K. Wheatley, S. J. Kent, J. Rossjohn, J. Torresi, K. Kedzierska,
879		CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display
880		high naive precursor frequency and TCR promiscuity. <i>Immunity</i> 54 , 1066-1082 e1065 (2021).
881	28.	F. Tea, A. Ospina Stella, A. Aggarwal, D. Ross Darley, D. Pilli, D. Vitale, V. Merheb, F. X. Z.
882		Lee, P. Cunningham, G. J. Walker, C. Fichter, D. A. Brown, W. D. Rawlinson, S. R. Isaacs, V.
883		Mathivanan, M. Hoffmann, S. Pohlman, O. Mazigi, D. Christ, D. E. Dwyer, R. J. Rockett, V.
884		Sintchenko, V. C. Hoad, D. O. Irving, G. J. Dore, I. B. Gosbell, A. D. Kelleher, G. V.
885		Matthews, F. Brilot, S. G. Turville, SARS-CoV-2 neutralizing antibodies: Longevity, breadth,
886		and evasion by emerging viral variants. <i>PLoS medicine</i> 18 , e1003656 (2021).
887	29.	M. Wolfl, J. Kuball, W. Y. Ho, H. Nguyen, T. J. Manley, M. Bleakley, P. D. Greenberg,
888		Activation-induced expression of CD137 permits detection, isolation, and expansion of the full
889		repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope
890		specificities. <i>Blood</i> 110 , 201-210 (2007).
891	30.	N. Seddiki, L. Cook, D. C. Hsu, C. Phetsouphanh, K. Brown, Y. Xu, S. J. Kerr, D. A. Cooper,
892		C. M. Munier, S. Pett, J. Ananworanich, J. Zaunders, A. D. Kelleher, Human antigen-specific
893		CD4(+) CD25(+) CD134(+) CD39(+) T cells are enriched for regulatory T cells and comprise a
894		substantial proportion of recall responses. Eur J Immunol 44, 1644-1661 (2014).
895	31.	H. Balachandran, C. Phetsouphanh, D. Agapiou, A. Adhikari, C. Rodrigo, M. Hammoud, L. B.
896		Shrestha, E. Keoshkerian, M. Gupta, S. Turville, D. Christ, C. King, S. C. Sasson, A. Bartlett,
897		B. Grubor-Bauk, W. Rawlinson, A. Aggarwal, A. O. Stella, V. Klemm, M. M. Mina, J. J. Post,
898		B. Hudson, N. Gilroy, P. Konecny, G. Ahlenstiel, D. E. Dwyer, T. C. Sorrell, A. Kelleher, N.
899		Tedla, A. R. Lloyd, M. Martinello, R. A. Bull, C. S. Group, Maintenance of broad neutralizing
900		antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific
901		CD4+ T cell responses. <i>Cell reports</i> 38 , 110345 (2022).
902	32.	D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao,
903		S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly predictive of
904		immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211 (2021).
905	33.	J. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I. Ramirez, S.
906		Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F. Krammer, V. Simon,
907		E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette, S. Crotty, Immunological memory to
908		SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> 371 , (2021).
909	34.	J. Mateus, A. Grifoni, A. Tarke, J. Sidney, S. I. Ramirez, J. M. Dan, Z. C. Burger, S. A.
910		Rawlings, D. M. Smith, E. Phillips, S. Mallal, M. Lammers, P. Rubiro, L. Quiambao, A.
911		Sutherland, E. D. Yu, R. da Silva Antunes, J. Greenbaum, A. Frazier, A. J. Markmann, L.
912		Premkumar, A. de Silva, B. Peters, S. Crotty, A. Sette, D. Weiskopf, Selective and cross-
913		reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science, (2020).
914	35.	B. J. Meckiff, C. Ramirez-Suastegui, V. Fajardo, S. J. Chee, A. Kusnadi, H. Simon, A. Grifoni,
915		E. Pelosi, D. Weiskopf, A. Sette, F. Ay, G. Seumois, C. H. Ottensmeier, P. Vijayanand, Single-
916		Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 (+) T Cells. SSRN, 3641939
917		(2020).

- 36. J. J. Zaunders, S. Ip, M. L. Munier, D. E. Kaufmann, K. Suzuki, C. Brereton, S. C. Sasson, N.
 Seddiki, K. Koelsch, A. Landay, P. Grey, R. Finlayson, J. Kaldor, E. S. Rosenberg, B. D.
 Walker, B. Fazekas de St Groth, D. A. Cooper, A. D. Kelleher, Infection of CD127+
 (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of
 antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J *Virol* 80, 10162-10172 (2006).
 D. E. Kaufmann, D. G. Kavanagh, F. Pereyra, J. J. Zaunders, E. W. Mackey, T. Miura, S.
- D. E. Kaufmann, D. G. Kavanagh, F. Pereyra, J. J. Zaunders, E. W. Mackey, T. Miura, S.
 Palmer, M. Brockman, A. Rathod, A. Piechocka-Trocha, B. Baker, B. Zhu, S. Le Gall, M. T.
 Waring, R. Ahern, K. Moss, A. D. Kelleher, J. M. Coffin, G. J. Freeman, E. S. Rosenberg, B. D.
 Walker, Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease
 progression and defines a reversible immune dysfunction. *Nat Immunol* 8, 1246-1254 (2007).
- 38. S. Boppana, K. Qin, J. K. Files, R. M. Russell, R. Stoltz, F. Bibollet-Ruche, A. Bansal, N.
 Erdmann, B. H. Hahn, P. A. Goepfert, SARS-CoV-2-specific circulating T follicular helper
 cells correlate with neutralizing antibodies and increase during early convalescence. *PLoS Pathog* 17, e1009761 (2021).
- A. Tarke, J. Sidney, C. K. Kidd, J. M. Dan, S. I. Ramirez, E. D. Yu, J. Mateus, R. da Silva
 Antunes, E. Moore, P. Rubiro, N. Methot, E. Phillips, S. Mallal, A. Frazier, S. A. Rawlings, J.
 A. Greenbaum, B. Peters, D. M. Smith, S. Crotty, D. Weiskopf, A. Grifoni, A. Sette,
 Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2
 epitopes in COVID-19 cases. *Cell Rep Med* 2, 100204 (2021).
- W. J. Hey-Nguyen, Y. Xu, C. F. Pearson, M. Bailey, K. Suzuki, R. Tantau, S. Obeid, B. Milner,
 A. Field, A. Carr, M. Bloch, D. A. Cooper, A. D. Kelleher, J. J. Zaunders, K. K. Koelsch,
 Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using
 Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy. *AIDS Res Hum Retroviruses* 33, 648-657 (2017).
- H. Law, M. Mach, A. Howe, S. Obeid, B. Milner, C. Carey, M. Elfis, B. Fsadni, K.
 Ognenovska, T. G. Phan, D. Carey, Y. Xu, V. Venturi, J. Zaunders, A. D. Kelleher, C. M. L.
 Munier, Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza
 vaccination immune response. *iScience* 25, 103656 (2022).
- Y. Xu, C. Phetsouphanh, K. Suzuki, A. Aggrawal, S. Graff-Dubois, M. Roche, M. Bailey, S.
 Alcantara, K. Cashin, R. Sivasubramaniam, K. K. Koelsch, B. Autran, R. Harvey, P. R. Gorry,
 A. Moris, D. A. Cooper, S. Turville, S. J. Kent, A. D. Kelleher, J. Zaunders, HIV-1 and SIV
 Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T
 Follicular Helper Cells. *Front Immunol* 8, 376 (2017).
- 43. C. Phetsouphanh, Y. Xu, J. Amin, N. Seddiki, F. Procopio, R. P. Sekaly, J. J. Zaunders, A. D.
 43. Kelleher, Characterization of Transcription Factor Phenotypes within Antigen-Specific CD4+ T
 44. Cells Using Qualitative Multiplex Single-Cell RT-PCR. *PLoS One* 8, e74946 (2013).
- R. Morita, N. Schmitt, S. E. Bentebibel, R. Ranganathan, L. Bourdery, G. Zurawski, E. Foucat,
 M. Dullaers, S. Oh, N. Sabzghabaei, E. M. Lavecchio, M. Punaro, V. Pascual, J. Banchereau,
 H. Ueno, Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and
 contain specific subsets that differentially support antibody secretion. *Immunity* 34, 108-121
 (2011).
- J. J. Zaunders, W. B. Dyer, B. Wang, M. L. Munier, M. Miranda-Saksena, R. Newton, J.
 Moore, C. R. Mackay, D. A. Cooper, N. K. Saksena, A. D. Kelleher, Identification of
 circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an
 HIV-1 long-term nonprogressor and in CMV infection. *Blood* 103, 2238-2247 (2004).
- V. Appay, J. J. Zaunders, L. Papagno, J. Sutton, A. Jaramillo, A. Waters, P. Easterbrook, P.
 Grey, D. Smith, A. J. McMichael, D. A. Cooper, S. L. Rowland-Jones, A. D. Kelleher,
 Characterization of CD4(+) CTLs ex vivo. *J Immunol* 168, 5954-5958 (2002).

- 967 47. C. Phetsouphanh, D. Aldridge, E. Marchi, C. M. L. Munier, J. Meyerowitz, L. Murray, C. Van
 968 Vuuren, D. Goedhals, S. Fidler, A. Kelleher, P. Klenerman, J. Frater, Maintenance of
 969 Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers. *Front Immunol* 10, 1844
 970 (2019).
- 48. J. A. Juno, D. van Bockel, S. J. Kent, A. D. Kelleher, J. J. Zaunders, C. M. Munier, Cytotoxic
 CD4 T Cells-Friend or Foe during Viral Infection? *Front Immunol* 8, 19 (2017).
- 49. I. Thevarajan, T. H. O. Nguyen, M. Koutsakos, J. Druce, L. Caly, C. E. van de Sandt, X. Jia, S.
 Nicholson, M. Catton, B. Cowie, S. Y. C. Tong, S. R. Lewin, K. Kedzierska, Breadth of
 concomitant immune responses prior to patient recovery: a case report of non-severe COVID19. Nat Med 26, 453-455 (2020).
- 977 50. P. Anderson, C. Nagler-Anderson, C. O'Brien, H. Levine, S. Watkins, H. S. Slayter, M. L. Blue,
 978 S. F. Schlossman, A monoclonal antibody reactive with a 15-kDa cytoplasmic granule979 associated protein defines a subpopulation of CD8+ T lymphocytes. *J Immunol* 144, 574-582.
 980 (1990).
- 51. J. Y. Zhang, X. M. Wang, X. Xing, Z. Xu, C. Zhang, J. W. Song, X. Fan, P. Xia, J. L. Fu, S. Y.
 Wang, R. N. Xu, X. P. Dai, L. Shi, L. Huang, T. J. Jiang, M. Shi, Y. Zhang, A. Zumla, M.
 Maeurer, F. Bai, F. S. Wang, Single-cell landscape of immunological responses in patients with
 COVID-19. *Nat Immunol* 21, 1107-1118 (2020).
- 52. J. A. Jaimes, J. K. Millet, G. R. Whittaker, Proteolytic Cleavage of the SARS-CoV-2 Spike
 Protein and the Role of the Novel S1/S2 Site. *iScience* 23, 101212 (2020).
- M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, T. S.
 Schiergens, G. Herrler, N. H. Wu, A. Nitsche, M. A. Muller, C. Drosten, S. Pohlmann, SARSCoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
 Protease Inhibitor. *Cell* 181, 271-280 e278 (2020).
- 84. R. Essalmani, J. Jain, D. Susan-Resiga, U. Andreo, A. Evagelidis, R. M. Derbali, D. N. Huynh,
 F. Dallaire, M. Laporte, A. Delpal, P. Sutto-Ortiz, B. Coutard, C. Mapa, K. Wilcoxen, E.
 Decroly, T. Nq Pham, E. A. Cohen, N. G. Seidah, Distinctive Roles of Furin and TMPRSS2 in
 SARS-CoV-2 Infectivity. *J Virol*, e0012822 (2022).
- 55. S. M. Russell, F. Y. Liew, T cells primed by influenza virion internal components can cooperate
 in the antibody response to haemagglutinin. *Nature* 280, 147-148 (1979).
- 997 56. P. A. Scherle, W. Gerhard, Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. *J Exp Med* 164, 1114-1128 (1986).
- A. Sette, M. Moutaftsi, J. Moyron-Quiroz, M. M. McCausland, D. H. Davies, R. J. Johnston, B.
 Peters, M. Rafii-El-Idrissi Benhnia, J. Hoffmann, H. P. Su, K. Singh, D. N. Garboczi, S. Head,
 H. Grey, P. L. Felgner, S. Crotty, Selective CD4+ T cell help for antibody responses to a large
 viral pathogen: deterministic linkage of specificities. *Immunity* 28, 847-858 (2008).
- T. Sztain, S. H. Ahn, A. T. Bogetti, L. Casalino, J. A. Goldsmith, E. Seitz, R. S. McCool, F. L.
 Kearns, F. Acosta-Reyes, S. Maji, G. Mashayekhi, J. A. McCammon, A. Ourmazd, J. Frank, J.
 S. McLellan, L. T. Chong, R. E. Amaro, A glycan gate controls opening of the SARS-CoV-2
 spike protein. *bioRxiv*, (2021).
- B. Li, A. Deng, K. Li, Y. Hu, Z. Li, Y. Shi, Q. Xiong, Z. Liu, Q. Guo, L. Zou, H. Zhang, M. Zhang, F. Ouyang, J. Su, W. Su, J. Xu, H. Lin, J. Sun, J. Peng, H. Jiang, P. Zhou, T. Hu, M.
- 1010 Luo, Y. Zhang, H. Zheng, J. Xiao, T. Liu, M. Tan, R. Che, H. Zeng, Z. Zheng, Y. Huang, J. Yu,
- 1011 L. Yi, J. Wu, J. Chen, H. Zhong, X. Deng, M. Kang, O. G. Pybus, M. Hall, K. A. Lythgoe, Y.
- 1012 Li, J. Yuan, J. He, J. Lu, Viral infection and transmission in a large, well-traced outbreak caused
- 1013 by the SARS-CoV-2 Delta variant. *Nature communications* **13**, 460 (2022).

- A. Grifoni, J. Sidney, R. Vita, B. Peters, S. Crotty, D. Weiskopf, A. Sette, SARS-CoV-2 human
 T cell epitopes: Adaptive immune response against COVID-19. *Cell Host Microbe* 29, 10761092 (2021).
- 1017 61. D. R. Darley, G. J. Dore, L. Cysique, K. A. Wilhelm, D. Andresen, K. Tonga, E. Stone, A.
 1018 Byrne, M. Plit, J. Masters, H. Tang, B. Brew, P. Cunningham, A. Kelleher, G. V. Matthews,
 1019 Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2
 1020 infection. *The Medical journal of Australia* 214, 279-280 (2021).
- C. Phetsouphanh, D. R. Darley, D. B. Wilson, A. Howe, C. M. L. Munier, S. K. Patel, J. A.
 Juno, L. M. Burrell, S. J. Kent, G. J. Dore, A. D. Kelleher, G. V. Matthews, Immunological
 dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. *Nat Immunol* 23, 210-216 (2022).
- R. Rouet, O. Mazigi, G. J. Walker, D. B. Langley, M. Sobti, P. Schofield, H. Lenthall, J.
 Jackson, S. Ubiparipovic, J. Y. Henry, A. Abayasingam, D. Burnett, A. Kelleher, R. Brink, R.
 R. Bull, S. Turville, A. G. Stewart, C. C. Goodnow, W. D. Rawlinson, D. Christ, Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. *MAbs* 1029
 13, 1922134 (2021).
- J. Zaunders, C. M. L. Munier, H. M. McGuire, H. Law, A. Howe, Y. Xu, B. F. de St Groth, P.
 Schofield, D. Christ, B. Milner, S. Obeid, W. B. Dyer, N. K. Saksena, A. D. Kelleher, Mapping
 the extent of heterogeneity of human CCR5+ CD4+ T cells in peripheral blood and lymph
 nodes. *AIDS* 34, 833-848 (2020).
- 1034 65. D. C. Hsu, J. J. Zaunders, M. Plit, C. Leeman, S. Ip, T. Iampornsin, S. L. Pett, M. Bailey, J.
 1035 Amin, S. Ubolyam, A. Avihingsanon, J. Ananworanich, K. Ruxrungtham, D. A. Cooper, A. D.
 1036 Kelleher, A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison
 1037 with existing assays. *Tuberculosis (Edinb)* 92, 321-327 (2012).
- J. Zaunders, W. Dyer, M. Churchill, C. Munier, P. Cunningham, K. Suzuki, K. McBride, W.
 Hey-Nguyen, K. Koelsch, B. Wang, B. Hiener, S. Palmer, P. Gorry, M. Bailey, Y. Xu, M.
 Danta, N. Seddiki, D. Cooper, N. Saksena, J. Sullivan, S. Riminton, J. Learmont, A. Kelleher,
 Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an
 elite controller with CCR5 □32 heterozygous and HLA-B57 genotype. *Journal of Virus Eradication* 5, 73-83 (2019).
- A. Aggarwal, A. Stella, G. Walker, A. Akerman, Esneau C, V. Milogiannakis, D. Burnett, S.
 McAllery, M. Ruiz Silva, Y. Lu, C. Foster, F. Brilot, A. Pillay, S. van Hal, S. Mathivanan, C.
 Fichter, A. Kindinger, A. Carey Hoppe, C. Munier, S. Amatayakul-Chantler, N. Roth, G.
- Coppola, G. Symonds, P. Schofield, J. Jackson, H. Lenthall, J. Henry, C. Mazigi, H.-M. Jäck,
 M. Davenport, D. Darley, G. Matthews, D. Khoury, D. Cromer, C. Goodnow, D. Christ, R.
 Robosa, D. Starck, N. Bartlett, W. Rawlinson, A. Kelleher, S. Turville, Platform for isolation
 and characterization of SARS-CoV-2 variants enables rapid characterisation of Omicron in
 Australia. *Nature Microbiology* In press, (2022).
- 1052 68. M. Stoeckius, C. Hafemeister, W. Stephenson, B. Houck-Loomis, P. K. Chattopadhyay, H.
 1053 Swerdlow, R. Satija, P. Smibert, Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods* 14, 865-868 (2017).
- T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck, 3rd, Y. Hao, M.
 Stoeckius, P. Smibert, R. Satija, Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888-1902 e1821 (2019).
- 1058 70. C. Hafemeister, R. Satija, Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol* 20, 296 (2019).
- 106071.A. T. Lun, D. J. McCarthy, J. C. Marioni, A step-by-step workflow for low-level analysis of1061single-cell RNA-seq data with Bioconductor. *F1000Res* 5, 2122 (2016).

RBD-specific memory CD4 T cells

1062 1063	72.	D. J. McCarthy, K. R. Campbell, A. T. Lun, Q. F. Wills, Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. <i>Bioinformatics</i> 33 , 1179-1186
1064		(2017).
1065	73.	C. W. Law, Y. Chen, W. Shi, G. K. Smyth, voom: Precision weights unlock linear model
1066		analysis tools for RNA-seq read counts. Genome Biol 15, R29 (2014).
1067	74.	J. Massey, K. Jackson, M. Singh, B. Hughes, B. Withers, C. Ford, M. M. Khoo, K. K.
1068		Hendrawan, J. J. Zaunders, B. Charmeteau-De Muylder, R. Cheynier, F. Luciani, D. D. Ma, J.
1069		Moore, I. Sutton, Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling
1070		of the Clonal T Cell Repertoire in Multiple Sclerosis. Frontiers in Immunology 13, (2022).
1071	75.	J. A. Vander Heiden, G. Yaari, M. Uduman, J. N. H. Stern, K. C. O'Connor, D. A. Hafler, F.
1072		Vigneault, S. H. Kleinstein, pRESTO: a toolkit for processing high-throughput sequencing raw
1073		reads of lymphocyte receptor repertoires. Bioinformatics 30, 1930-1932 (2014).
1074	76.	J. Ye, N. Ma, T. L. Madden, J. M. Ostell, IgBLAST: an immunoglobulin variable domain
1075		sequence analysis tool. Nucleic Acids Res 41, W34-40 (2013).
1076	77.	N. T. Gupta, J. A. Vander Heiden, M. Uduman, D. Gadala-Maria, G. Yaari, S. H. Kleinstein,
1077		Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing
1078		data. Bioinformatics 31, 3356-3358 (2015).
1079	78.	Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck, 3rd, S. Zheng, A. Butler, M. J. Lee, A. J.
1080		Wilk, C. Darby, M. Zager, P. Hoffman, M. Stoeckius, E. Papalexi, E. P. Mimitou, J. Jain, A.
1081		Srivastava, T. Stuart, L. M. Fleming, B. Yeung, A. J. Rogers, J. M. McElrath, C. A. Blish, R.
1082		Gottardo, P. Smibert, R. Satija, Integrated analysis of multimodal single-cell data. Cell 184,
1083		3573-3587.e3529 (2021).
1084	79.	H. Wickham, M. Averick, J. Bryan, W. Chang, L. McGowan, R. François, G. Grolemund, A.
1085		Hayes, L. Henry, J. Hester, M. Kuhn, T. Pedersen, E. Miller, S. Milton Bache, K. Müller, J.
1086		Ooms, D. Robinson, D. Seidel, V. Spinu, K. Takahashi, D. Vaughan, C. Wilke, K. Woo, H.
1087		Yutani, Welcome to the tidyverse. Journal of Open Source Software 4, (2019).
1088	80.	C. E. Shannon, A mathematical theory of communication. <i>The Bell System Technical Journal</i>
1089	0.1	27 , 379-423 (1948).
1090	81.	E. Marcon, B. Hérault, entropart: An R Package to Measure and Partition Diversity. <i>Journal of</i>
1091	00	Statistical Software 67, 1 - 26 (2015).
1092	82.	M. Krzywinski, J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman, S. J. Jones, M. A.
1093		Marra, Circos: an information aesthetic for comparative genomics. <i>Genome Res</i> 19 , 1639-1645 (2009).
1094 1095	83.	S. Nolan, M. Vignali, M. Klinger, J. N. Dines, I. M. Kaplan, E. Svejnoha, T. Craft, K. Boland,
1095	65.	M. Pesesky, R. M. Gittelman, T. M. Snyder, C. J. Gooley, S. Semprini, C. Cerchione, M.
1090		Mazza, O. M. Delmonte, K. Dobbs, G. Carreño-Tarragona, S. Barrio, V. Sambri, G. Martinelli,
1097		J. D. Goldman, J. R. Heath, L. D. Notarangelo, J. M. Carlson, J. Martinez-Lopez, H. S. Robins,
1098		A large-scale database of T-cell receptor beta (TCR β) sequences and binding associations from
1100		natural and synthetic exposure to SARS-CoV-2. <i>Res Sq</i> , (2020).
1100	84.	D. V. Bagaev, R. M. A. Vroomans, J. Samir, U. Stervbo, C. Rius, G. Dolton, A. Greenshields-
1102	01.	Watson, M. Attaf, E. S. Egorov, I. V. Zvyagin, N. Babel, D. K. Cole, A. J. Godkin, A. K.
1102		Sewell, C. Kesmir, D. M. Chudakov, F. Luciani, M. Shugay, VDJdb in 2019: database
1104		extension, new analysis infrastructure and a T-cell receptor motif compendium. <i>Nucleic Acids</i>
1105		Research 48, D1057-D1062 (2019).
1106		······································
1107		
1108		


1109

RBD-specific memory CD4 T cells


1111 ACKNOWLEDGMENTS

- 1112
- 1113 The authors thank Bertha Fsadni, Sri Meka, Julie Jurczyluk and Kate Merlin at the St Vincent's
- 1114 Institute for Applied Medical Research-Clinical Trials Unit for their expertise in specimen processing
- 1115 and bio-banking. We thank Dr Emma Johansson Beves for assistance on the Cytek Aurora.
- 1116
- 1117 Funding
- 1118
- 1119 St Vincent's Clinic Foundation Grant (GVM, GJD, DD)
- 1120 Medical Research Future Fund Grant (ST, FB-T, TGP, JZ)
- 1121 National Health and Medical Research Council (NHMRC) Program Grant ID1149990 (ADK)
- 1122 NHMRC Fellowship ID1155678 (TGP)
- 1123 UNSW Cellular Genomics Futures Institute Seed Funding (WHK)
- 1124 Mrs. Janice Gibson and the Ernest Heine Family Foundation (PIC and TGP)
- 1125 Garvan Institute COVID Catalytic Grant (TGP)
- 1126 UNSW COVID-19 Rapid Response Research Initiative (TGP)
- 1127
- 1128 Competing interests
- 1129 The authors declare no competing interests
- 1130
- 1131 Author contributions
- 1132 Protocol design and clinical management: GVM, GJD, DD
- Experimental design and procedures: CP, WHK, KLJ, VK, AH, AAg, AAk, VM, AOS, RR, PS, MLK,
 HL, TD, MS, CMLM, MS, FB-T, ST, TGP, ADK, JZ
- 1135 Visualization: CP, WHK, KLJ, JZ
- 1136 Funding acquisition: GVM, GJD, DD, DC, ST, FB-T, TGP, PC, ADK, JZ
- 1137 Supervision: DC, ST, PC, GVM, PIC, TGP, ADK
- 1138 Writing original draft: CP, WHK, KLJ, TGP, JZ
- 1139 Writing review & editing: CP, WHK, KLJ, CMLM, ST, AAg, TGP, ADK, JZ
- 1140
- 1141

RBD-specific memory CD4 T cells








1150 (A) Representative dot plots of CD25+CD134+ co-expression on RBD-specific CD4+ T cells. (B) Frequency of RBD reactive CD4+ T cells in convalescent subjects (conv) compared to unexposed healthy controls (UHC). (C) 1151 1152 Percentage of proliferating CD4+ T cells stimulated with RBD or Flu antigen. (D) Positive correlation between 1153 recall CD25+CD134+ CD4 response and 7 days of proliferation. (E) Correlation between spike IgG levels and 1154 RBD specific proliferation of CD4+ T cells. (F) Convalescent subjects with proliferated CD4+ T cells (>1%) are 1155 Ab high vs subjects without proliferation (<1%) are Ab low, based on combined IgG/IgM score. (G) Subjects 1156 with proliferated CD4+ T cells (>1%) have significantly higher neutralizing Ab titres (NT₅₀) vs subjects without 1157 proliferation (<1%). Data shown as medians with interquartile ranges. Two-tailed p values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001, ****<0.0001). Mann-Whitney T tests were used for 1158 1159 unpaired groups and Pearson's rho was used for correlations.

RBD-specific memory CD4 T cells






1162 Figure 2- Higher neutralization breadth in Ab high group that decreases over time.

(A) Representative dot plot showing difference in neutralisation of Ab high (blue) and Ab body low
(groups) over time. (B) Reduction of neutralizing antibodies over time. 3M (3 months), 4M (4 months),
8M (8 months). (C) Increased neutralising breadth of Ab high group compared to antibody low. (D)
Decreased neutralization tire in Ab high group at 8-months post-infection but remain higher than Ab
low. Two-tailed p values <0.05 were considered significant (ns-not significant, *<0.05, **<0.01,
<0.001, *<0.0001). Wilcoxon T tests were used for paired groups and Mann-Whitney sued for
unpaired. Heatmap values shown as median neutralization tire.

RBD-specific memory CD4 T cells




1174



1176 (A) CD4 responses to influenza, spike, RBD and nucleoprotein (NP) at 3M and 8M post-infection. (B) Higher 1177 frequency of SARS-CoV-2 proliferative CD4 T cells in Ab high group compared to Ab low at 3M and 8M. (medians 1178 with interquartile ranges). (C) Representative UMAP of proliferated CD4 T cells: concatenated; ab high; and ab low. 1179 Red gates are regulatory-like cells present in Ab low subjects. (D) Regulatory-like Foxp3+ cells are higher in Ab low 1180 subjects (grey columns) compared with higher effector cells in Ab high subjects (black columns). The colour and 1181 number of horizontal bar graphs match with UMAP clusters. Two-tailed p values <0.05 were considered significant 1182 (ns-not significant, *<0.05, **<0.01, ***<0.001, ****<0.0001). Mann-Whitney T test used for unpaired samples.

RBD-specific memory CD4 T cells




1189 Figure 4- No difference in CD8 responses but presence of inhibitory receptors in Ab low subjects.

(A) No difference between CD8 in Ab high and Ab low groups. (B) Higher frequency of NP proliferative CD8 T
cells in Ab high group compared to Ab low. 3M (3 months) and 8M (8 months). Data shown as medians with
interquartile ranges. (C) Representative UMAP of proliferated CD8 T cells; concatenated, ab high and ab low.
(D) Presence of an inhibitory phenotype within cells of Ab low subjects. Colour and number of horizontal bar

1194 graphs match with UMAP clusters. Black columns (Ab high) and grey columns (Ab low). Two-tailed p values

1195 <0.05 were considered significant (*<0.05, **<0.01). Mann-Whitney T test used for unpaired samples.

RBD-specific memory CD4 T cells



1209 Figure 5- B and T cell parameters correlate with antibody response.

(A) Higher CD38+ B cell plasmablasts in Ab high group. (B) Elevated double negative (DN, IgD-CD127-) B
cells in Ab low group. Nai□ve (N, IgD+CD127-), non-switched memory (NSM, IgD+CD127+), switched
memory (SM, IgD-CD127+) B cells. Higher CXCR5 expression on CD4s (C), activation (CD38+HLA-DR+) on
CD4 (D) and CD8 (E), and CD4 effector memory cells (F) in Ab High compared to Ab low group. Data shown
as medians with interquartile ranges. (G) Higher nai□ve CD8+ T cells in Ab low group at both timepoints. SN
(spike), SR (RBD), NP (nucleoprotein). Two-tailed p values <0.05 were considered significant (*<0.05,
<0.01, *<0.001. Mann-Whitney T tests were used for unpaired groups.

RBD-specific memory CD4 T cells








Figure 5- (cont'd) B and T cell parameters correlate with antibody response.

1244 (H) B cell plasmablast, CXCR5+ CD4 T cells, activated CD4 and CD8 T cells, proliferative Spike and RBD-1245 specific CD4 positively correlate with humoral response at 3 months post-infection (red box). (I) PCA clustering 1246 of Ab high and Ab low groups based on T and B cell parameters. Pearson's rho was used for correlations and 1247 adjusted *p* values shown with Benjamini-Hochberg correction used for multiple comparisons. Two-tailed p 1248 values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001.

RBD-specific memory CD4 T cells



RBD-specific memory CD4 T cells




1256 Figure 6- Single-cell RNAseq reveals heterogenous subsets and diverse TCR usage within SARS-


1257 CoV-2 reactive CD4+ T cells

1258

1259 (A) UMAP showing 14,053 CD4+ T cells from CD25+CD134+ sorted cells from Ab high subjects 1260 split into 4 conditions: ex vivo memory; nucleoprotein (NP); Spike; and RBD. (B) Dot plot showing 1261 average expression of lineage genes and percentage of cellular expression within each cluster. (C) 1262 Enrichment of Treg populations in SARS-CoV-2-specific CD4 in addition to central/transition memory 1263 and cytotoxic subsets. (D) Diversity of TCR alpha and (E) TCR beta chain in all 4 conditions. Few 1264 select TCRa/b enriched in stimulated conditions compared to ex vivo memory expressed as log odds 1265 ratio with adjusted p values including Bonferroni correction. (F) Circos plots showing little transition 1266 of cell types between ex vivo memory and stimulated conditions.


RBD-specific memory CD4 T cells





Bulk TCR sequencing of CD4s T cells from Ab high subjects that proliferated for 5 days following stimulation with SARS-CoV-2 peptide pools were matched with 10x single-cell TCRs to examine enriched clonotypes. (A) UMAP clonotypes that were enriched following proliferation and matched to 10x TCRs and split into 4 conditions: ex vivo memory, nucleoprotein (NP), Spike and RBD. (B) Proliferative CD4 clones were highly enriched with activated GITR+ Tregs and cytotoxic clusters. (C) Abundance of unique single clonotypes with few expanded clonotypes within stimulated conditions. (D) Minimal shared TCR clonotypes within stimulated conditions compared to ex vivo memory. Fishers exact test with Bonferroni's corrected *p* values shown for log odd ratios.

RBD-specific memory CD4 T cells



1278



(A) Significant increase in RBD-specific CD4+ T cells following vaccination in Ab low group. (B) No difference in CD8 response in both groups post-vaccination. (C) Increase in antibodies following two doses of SARS-CoV-2 vaccination that neutralized both ancestral and delta viruses in Ab low and Ab high groups. (D) Positive correlation between RBD- specific CD4+ T cells and neutralising antibody titres post second dose of vaccination. Data shown as medians with interquartile ranges. Two-tailed p values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001. Mann- Whitney T tests were used for unpaired groups. Pearson's rho was used for correlations and adjusted *p* values shown.

- 1287 1288
- 1289
- 1290
- 1291
- 1292
- 1293 1294

RBD-specific memory CD4 T cells

1295 Supplementary Figures

Characteristics	ADAPT Cohort				
	Recombinant RBD	Antibody Low	Antibody Low	Antibody High	Antibody High
	3 month OX40	Convalescent	Vaccinated	Convalescent	Vaccinated
	screen				
n	25	12	14	12	20
Mean age (y)	42 ± 10.8	47 ± 14.3	54 + 17.9	54 ±16.1	59 <u>+</u> 13.8
Malegender, n (%)	12 (48%)	6 (50%)	9 (64%)	12 (100%)	12 (60%)
Ethnicity (n, %-total)					
- African American	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
- Asian	2 (8%)	0 (0%)	1 (7%)	0 (0%)	0 (0%)
- Caucasian	19 (76%)	10 (83%)	13 (93%)	12 (100%)	20 (100%)
- Hispanic	2 (8%)	2 (17%)	0 (0%)	0 (0%)	0 (0%)
- Others	2 (8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Median Days post infection					
3 months (FU3)	76 <u>+</u> 18	74.5 <u>+</u> 15	68 <u>+</u> 19	62.5 <u>+</u> 14	46.5 <u>+</u> 25
8 months (FU5)	228 <u>+</u> 60	228 <u>+</u> 75	250 <u>+</u> 30	226.5 <u>+</u> 24	244 <u>+</u> 69
Vaccination 2nd dose			528 <u>+</u> 26		479 <u>+</u> 87
Severity (n, %-total)					
- Mild	9 (36%)	6 (50%)	6 (42.85%)	2 (16.7%)	9 (45%)
- Moderate	16 (64%)	6 (50%)	6 (42.85%)	7 (58.3%)	8 (40%)
- Severe	0 (0%)	0 (0%)	2 (14.3%)	3 (25%)	3 (15%)

1299 Supplementary Table 1- *ADAPT study patient characteristics*. Age, gender, ethnicity, severity, and media 1300 neutralisation titre at month 3.


#	Peptide	Amino acid sequence	
1	SN1	NNATNVV I KV CE FQF	
2	SN2	CTFEYVSQPFLMDLE	
3	SN3	TRFQTLLALHRSYLT	
4	SN4	LLALHRSYLTPGDSS	
5	SN5	SVASQSIIAYTMSLG	
6	SN6	SIIAYTMSLGAENSV	
<u> </u>	SN7	NLLLQYGSFCTQLNR	
8	SN8	TQLNRALTGIAVEQD	
9	SN9	NFSQILPDPSKPSKR	
10	SN10	KPSKRSFIEDLLFNK	
10	SN11	SFIEDLLFNKVTLAD	
12			
	SN12		
13	SN13		
14	SN14		
15	SN15	SLLIVNNATNVVIKV	
16	SN16	CEFQFCNDPFLGVYY	
17	SN17	IGINITRFQTLLALH	
18	SN18	FTVEKGIYQTSNFRV	
19	SN19	AYSNNSIAIPTNFTI	
20	SN20	VFAQVKQIYKTPPIK	
21	SN21	CAQKFNGLTVLPPLL	
22	SN22	AQYTSALLAGTITSG	
23	SN23	WTFGAGAALQIPFAM	
24	SN24	GAISSVLNDILSRLD	
25	SN25	APHGVVFLHVTYVPA	
26	SN26	ELDKYFKNHTSPDVD	
27	SN27	GINASVVNIQKEIDR	
28	SN28	LNEVAKNLNESLIDL	
29	SN29	YEQYIKWPWYIWLGF	
30	SR1	GIYQTSNFRVQPTES	
31	SR2	SNFRVQPTESIVRFP	
	SR3		
32			
33	SR4	IVRFPNITNLCPFGE	
34	SR5	CPFGEVFNATRFASV	
35	SR6	VFNATRFASVYAWNR	
36	SR7	YAWNRKRISNCVADY	
37	SR8	GVSPTKLNDLCFTNV	
38	SR9	GKIADYNYKLPDDFT	
39	SR10	YNYKLPDDFTGCVIA	
40	SR11	GCVIAWNSNNLDSKV	
41	SR12	GGNYNYLYRLFRKSN	
42	SR13	YLYRLFRKSNLKPFE	
13	SR14	FNCYFPLQSYGFQPT	
44	NP1	MSDNGPQNQRNAPRITF	
45	NP2	NQRNAPRITFGGPSDSTG	
46	NP3	DDQIGYYRRATRRIR	
17	NP4	MKDLSPRWYFYYL	
18	NP5	LSPRWYFYYLGTGPEAGL	
19	NP6	LLESELVIGAVILRGHLR	
50	NP7	DAALALLLLDRLNQL	
51	NP8	LLLLDRLNQLESKMS	
52	NP9	AFFGMSRIGMEVTPSGTW	
53	NP10	GMEVTPSGTWLTYTGAIK	
54	NP11	PSGTWLTYTGAIKLD	
55	NP12	TWLTYTGAIKLDDKDPNF	
56	NP13	PNFKDQVILLNKHIDAYK	

1327 1328 1329


Supplementary Table 2. Peptides. SN (spike), SR (RBD), NP (Nucleocapsid protein).

RBD-specific memory CD4 T cells

Supplementary Figure 1




1B)



Supplementary Figure 1- T cell proliferation and phenotyping.


(A) Proliferated cells at day 7 in response to antigen stimulation in Q1 CD25+CellTraceViolet-(B) Gating strategy of proliferated T cells using transcription factors and activation markers.

RBD-specific memory CD4 T cells




RBD-specific memory CD4 T cells

Supplementary Figure 3



2B)


Purity Check



Supplementary Figure 3- Cell sorting for single-cell transcriptomics.

(A) Representative dot of 1 participant shown following 48hr stimulation with SAR-CoV-2 peptide pools, with SEB as a positive control. Antigen-specific CD4+ T cells were bulk sorted from Q2 (CD25+CD134+) on the BD Aria III. (B) CD45RO+ ex vivo (unstimulated) memory CD4+ T cells were also bulk sorted for 10X sequencing. A purity of >99% was achieved for all samples.

RBD-specific memory CD4 T cells



Supplementary Figure 4- Diversity of SARS-CoV-2 specific TCR clonotypes. (A) Slightly lower Shannon's entropy scores for spike, RBD and NP compared to ex vivo memory. (B) Circos plot showing high diversity of TCR $\alpha\beta$ usage in all 4 conditions.